List of Small Molecule Pharmaceuticals Companies in United States - 1583

4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer's disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.

In 2010, 60° Pharmaceuticals began its mission to build a better world by undertaking research and action focused on aiding in the prevention of infectious diseases. In 2022, we are continuing this mission with a broader focus on product development and commercialization for infectious diseases.

An early stage start-up with three products in Pre-IND phase and several complex generics in the pipeline.

7 Hills Pharma is a clinical-stage immunotherapy company developing a platform of novel, oral small molecules for the treatment of cancer and prevention of infectious diseases. Our compounds are first-in-concept allosteric integrin activators that leverage a unique mechanism of action to stabilize the cell-cell interactions required to mount an effective immune response. Our lead clinical candidate, 7HP349, is the only reported systemically safe immune stimulant that can activate both cellular and humoral immunity.

858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology. 858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell genomics, and innate immunity, 858 scientists are dedicated to the company’s mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies. 858 is headquartered in the biotech hub of San Diego, CA, and maintains lab operations in both San Diego and New York City, providing proximity to leading investigators and scientific talent on both coasts of the US.

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

Aardvark Therapeutics is a clinical stage biopharmaceutical company focused on leveraging host adaptive responses through gut-brain signaling for the treatment of metabolic and inflammatory diseases. The company has multiple programs in its pipeline and has received FDA orphan drug designation for its novel drug candidate for Prader-Willi syndrome.

Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.htm

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Abeomics Inc. is founded by scientists for the scientists. Our immunologists, cell biologists and business professionals have contributed for over 25 years to the growth and success of global companies including BD Biosciences, eBioscience and IMGENEX Corporation. We bring our experiences to develop well-validated and specific antibodies by traditional hybridoma technology and by genetic engineering to produce recombinant mouse and rabbit monoclonal antibodies.

Abilita Therapeutics is a biotechnology company focused on redefining the druggable landscape for multi-span membrane proteins, including G Protein Coupled Receptors (GPCRs), transporters and ion channels. We are building a rich pipeline of high-value assets for such targets, with the goal of becoming the leader in discovering and developing first- and best-in-class antibody therapeutics.

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company that develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is focused on developing therapies for a range of conditions.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.

Accuitis Pharmaceuticals, Inc. is a US registered company with commercial operations located in Atlanta, GA. Accuitis is a participant in the Georgia Research Alliance Venture Lab program and our key technology was discovered by Emory University. We are engaged in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. Our lead product is a transformational first in class treatment for Rosacea.

Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinson's, diabetes and cancer. Acelot's platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases. We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS. Our platform was invented by UCSB Computer Science Professor Dr. Ambuj Singh. Acelot's first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimer's. ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a robust discovery pipeline.

ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates. ACELYRIN is embedding a corporate culture of Courageous Caring™ -- placing patients first and embracing the concept that all of us are better than any one of us -- as we seek to addresses the most basic human needs: to live a productive life free from diseases.

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Acta has licensed IP from Massachusetts General Hospital which provides the foundation for its initial two clinical development programs. The first program is the result of the screening from the Tanzi Lab utilizing its Alzheimer’s-in-a-dish™ mini-human brain organoid model to identify and validate dozens of combinations that affect Alzheimer’s brain pathology. Acta will further assess these Combination Therapies and will testing the most promising ones in humans in its Alzheimer’s Disease Combination Trial Initiative. The second development program benefits from a robust Gamma-Secretase Modulator (GSM) patent estate including GSM-776890 - one of the most promising amyloid-lowering novel Alzheimer’s drugs which Acta is readying to enter clinical trials.

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

Discovering novel functions of existing molecules

Actuate Therapeutics, Inc. is a private clinical stage biopharmaceutical company focused on the treatment of cancer and inflammatory diseases leading to fibrosis.

Actylis is a chemicals company that specializes in acetates and provides pharmaceuticals, fine chemicals, and industrial chemicals.

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.

AcuraStem (acurastem.com) is a near-to-clinic, patient-based, drug development company pioneering drug discovery and ultimately how treatments are developed for neurodegenerative diseases—including sporadic ALS and FTD. Enabled by our ground-breaking iNeuroRx® technology platform - AcuraStem has discovered and is now advancing drug candidates that promise to strongly impact disease progression for most patients, including those for whom the genetic cause of their disease is unknown (i.e. sporadic ALS and FTD patients). The causes of neurodegenerative diseases are complex, and genetically defined forms of disease (e.g. C9ORF72-ALS and FTD) only account for a small percentage of cases. Thus, many scientists didn’t believe it was possible to develop a single effective treatment that could work broadly for all patients. But AcuraStem has shown with its extremely promising therapeutic programs for ALS and FTD that it can be done.

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with expertise focusing on oral dosage forms for the Pharmaceutical industry. Adare's specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactures more than 45 products sold by customers worldwide.

ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by our mission to turn cutting-edge science into life-saving therapeutics and our desire to provide hope for patients with intractable disease.

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

Adecto is a pre-clinical stage, cancer therapeutics company, developing the first targeted therapy against ADAM8-expressing cancers and a companion diagnostic to identify patients who can benefit from it. ADAM8 is a critical driver of the growth and spread of many aggressive tumors, including those of the breast, stomach, colon, lungs, liver and pancreas, and is associated with poor patient survival. Adecto’s current focus is on breast cancer with a plan to expand to other oncology indications in the future.

Adesis Inc. is a premier chemistry solution company backed by expert chemists and partnering with biotech and pharma industries to accelerate their research and manufacturing goals. Through the years, we've retained our original culture anchored in ethics, integrity, values, family, transparency, speed, safety and trust. We are one of the few companies that can turn a difficult whiteboard chemistry concept into a physical product. We specialize in organic and organometallic synthesis and deliver organic chemistry services in three areas: early-stage research, scale-up and development, and specialty manufacturing. Our turnaround times are recognized as among the fastest in the industry – a direct result of minimizing red tape, maximizing lab time and quick, efficient decision-making. When clients say ‘let's begin,' we've already started. The companion to this remarkable speed is our commitment to safety. The Adesis Facility Safety Program is designed to constantly raise the level of awareness of safe work practices. Our vigilance extends to the protection of client patents and intellectual property. Backed by the effective use of systems, security and formalized processes, client confidentiality is always a priority. We pride ourselves on our chemists being respected for their brilliance and enthusiasm to collaborate and adapt. If a client needs to shift, we pivot quickly to provide the necessary facilities and specialist brainpower to address any challenge and keep the project moving. The compounds we develop for clients have found use in life-enhancing oncology, anti-infective, animal treatment, central nervous system, immunotherapy, therapeutic, ophthalmic, biomarkers, skin care, catalysts and other applications. Reliably and safely solving the toughest chemistry problems in partnership with its clients is the core purpose of Adesis. Trusted collaboration with exceptional chemistry teams. In Adesis hands, the science is not complicated.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test.

At Adiso, we create medicines to treat inflammatory diseases, improving the lives of patients and their families. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, we are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action. ADS024 (SS-LBP) is currently being evaluated in a Phase 1b study for the prevention of recurrent CDI and a Phase 2 study in mild-to-moderate ulcerative colitis (UC). ADS051 is currently enrolling a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor in discovery phase which is being initially explored in respiratory inflammation, with multiple future therapeutic areas to pursue.

Adovate develops novel drugs that target adenosine receptors involved in major diseases. These drug candidates have been created using our next-generation adenosine drug development platform, which enable design of patented compounds with favorable physiochemical characteristics and distribution kinetics that historically limited drugs acting against the adenosine receptors.

Adroit Pharmaceutical Development was founded to efficiently identify new formulations and process technologies for our clients. We also work with clients to identify and correct problems with their existing formulations and processes.

Preclinical biotechnology company leveraging proprietary structure-based technology to develop small molecule disaggregators and inhibitors targeting previously undruggable misfolded proteins in neurodegenerative diseases. Our pipeline consists of tau, TDP-43 and alpha-synuclein programs.

ADvantage Therapeutics - Headquartered in the Wynwood neighborhood in Miami, ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimer’s disease. The Company’s lead compound AD04™ is an injectable therapy in the process of entering into a confirmatory Phase 2b clinical trials in Europe to evaluate safety and efficacy of the product in early Alzheimer’s Disease. The Company believes that AD04™ may act as an immunomodulator, stimulating and regulating the immune system to reduce AD pathology, rather than limiting therapy to the aggregation of the proteins present once pathology is present. The Company is also exploring additional approaches to mitigating neurodegenerative disease, which it believes will eventually have an overall impact on longevity.

Advenchen is a pharmaceutical company that focuses on small molecule cancer drug discovery programs with a specialization in protein kinase inhibitors.

Adventris Pharmaceuticals is a biotechnology company focusing on cancer immunotherapy

Advion is a manufacturer and supplier of mass spectrometers and analytics systems for life science and pharmaceutical sectors.

AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. The company is dedicated to innovation in the rapidly expanding therapeutic botulinum toxin market. This therapeutic-only focus will allow AEON Biopharma to advance safe and effective treatment options to patients, while delivering differentiated economics to payors and physicians. The company continues to evaluate additional therapeutic indications for development based on a comprehensive product assessment process designed to identify those indications where it believes ABP-450 can attain clinical, regulatory and commercial success.

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases. Our lead development candidate, AV078, is a first-in-class CNS penetrant selective mTORC1 inhibitor being developed for the treatment of TSC refractory epilepsy and is currently being evaluated in a Phase 1 trial. TSC is a rare genetic disorder caused by the hyperactive signaling of mTORC1. Beyond AV078, we've developed a proprietary library of small molecules, which are potent and selective mTORC1 and CD38 inhibitors that have the potential to precisely target the underlying biology of multiple rare and age-related disease

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

The statistics are overwhelming: more than 130 people a day die from opioid related drug overdoses. In 2020 in the US alone, 2.7 million people aged 12 or older had Opioid Use Disorder (OUD) and 4.2 million people entered a drug rehabilitation program. While treatment programs and rescue medications are critical, æther THERAPEUTICS is focusing our efforts upstream: preventing addiction and creating a more effective treatment of OUD. æther THERAPEUTICS' main candidate is Low Dose 6β-Naltrexol (ATX-001). Animal models indicate that ATX-001 may prevent opioid dependence while not blocking pain relief or causing withdrawal & other adverse effects. Our vision is a world where the devastating effects of opioid addiction are alleviated, leading to: • Safer opioid pain therapy without the fear of addiction, • Cessation of opioid addiction • Prevention of Neonatal Opioid Withdrawal Syndrome (NOWS) æther THERAPEUTICS is focused on our vision, driven by innovation, embraces lean operations and engaged with urgency.

AfaSci, Inc., a San Francisco Bay Area biotech company committed to enhancing health care by conducting R&D in both Biotechnology and Therapeutics. Our bioengineering team has designed, produced and been marketing an in vivo drug screening platform, SmartCageTM. This system enables automated, and objective assessment of drug effects on rodent behavior and increases throughput of phenotyping of transgenic animals. Elevating our proprietary platform and well-established electrophysiological techniques, AfaSci’s scientists have been discovering IND drug candidates targeting ion channels and GPCR for the treatment of CNS disorders, especially neuropathic pain, epilepsy and Alzheimer’s disease.

Afecta Pharmaceuticals is an early clinical stage small molecule therapeutics company focused on developing precision medicines to treat chronic disorders and cancers more effectively. Afecta has a validated, proprietary Artificial Intelligence disease/drug targeting platform, PharmetRx®, to discover and optimize Multi-Target drug compounds and formulate them in NanoRx®, our tissue-specific drug delivery technology. Backed by an experienced management team, Afecta is currently advancing AFX-220, our clinically proven lead candidate that effectively treats the disruptive behaviors that occur in children and adolescents with several neurodevelopmental disorders such as Autism, AD/HD, and others. Please visit our website to learn more, register to access our Executive Summary, and receive our latest updates.

Founded in 2006, Affinity Biosciences is a pioneering Life Science and High-Tech company whose biochemical products and services are mainly applied in biotechnology, medical research and pharmaceutical development. Dedicating to advancing customer success through innovation, Affinity Biosciences has established R&D affiliates in the United Kingdom and United States with the aim of providing outstanding service around the globe.Our customers include scientists and technologists in life science companies, university and government institutions, hospitals and industry. To underline our commitment to our customers and enhance our standards of service, we have opened packaging and quality control facilities in the People’s Republic of China. Our goal is to develop high-quality antibody that focuses on Cell Signaling Transduction research, including Akt,AMPK,NF-KappaB,TGF-beta,etc,as well as inhibitors and related reagents.

Affinity Life Sciences for over 10 years providing the highest quality services for Lyophilization, Reagent Manufacturing, Immunoassay test and more.

Agastiya Biotech merges advanced, Eastern knowledge with rigorous Western R&D in order to deliver breakthrough innovative pharmaceuticals to the marketplace. Over 40% of all pharmaceutical drugs, including sophisticated chemotherapy and anti-viral drugs, are derived from natural plant sources. Through investigation of ancient Eastern botanical knowledge combined with high throughput and AI driven analysis, Agastiya Biotech engineers best in class novel small molecules for treatment of disease. We are leading the discovery and design of ground-breaking small molecules to revolutionize medicine and find a cure for the diseases of our time.

AgeneBio, Inc., is an emerging pharmaceutical company dedicated to developing innovative therapeutics that prevent neurodegeneration and preserve and restore cognitive function for unserved patients battling amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of aMCI. If approved, AgeneBio’s Phase 3-ready lead candidate, AGB101, will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. Learn more at www.agenebio.com and follow us on Twitter @AgeneBio.

Agile Therapeutics® is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. Our product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Agrivida is a biotechnology company focused on developing and commercializing a new generation of enzyme solutions to feed livestock more efficiently, reduce negative environmental impacts, and produce more healthful food for an expanding consumer population. Agrivida’s first product, GRAINZYME® Phytase, grows enzymes that are crucial for livestock’s health and well-being directly inside the animals’ corn feed. The enzymes improve feed digestibility, increase mineral availability, and reduce nutritional inhibitors within the animals. The traditional process for enzyme delivery is costly and inefficient. It requires enzyme additives to be administered alongside animal feed, and the process for producing the enzymes is complicated, generates excess waste, and requires tremendous energy. By growing necessary enzymes directly inside the feed, Agrivida eliminates the need for these enzyme additives, ultimately reducing costs to farmers, minimizing feed waste, and improving the environmental footprint of the entire process. Agrivida’s team is led by food and agribusiness industry executives and scientists with expertise in the fields of biochemistry, plant biology, molecular biology, and nutrition.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

AIM ImmunoTech Inc., an immuno-pharma company headquartered in Ocala, Florida, is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3). Ampligen® represents an RNA being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina. Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older. We operate a 30,000-square-foot facility in New Brunswick, NJ to produce Ampligen® and Alferon®. We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.

Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.

Ainos Inc. is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, women's health, pneumonia, Ainos Pen, AI Nose, and other medical technologies. The company was founded in 1984 and is engaged in developing innovative medical technologies for point-of-care testing and safe and effective treatments for various health conditions.

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.

AiViva BioPharma, Inc. is a privately owned clinical stage biotech developing novel technologies to address unmet medical needs by transforming existing treatments to create localized, targeted treatment of diseases while limiting systemic exposure. Our core competency includes development of drugs using our proprietary JEL™ Technology in specialty therapeutic areas of Dermatology, Ophthalmology, Urology, and Oncology.

Improve yield, reduce deviations, and ensure product quality in GxP pharmaceutical manufacturing with real-time, practical Artificial Intelligence (AI)- powered software as a service solutions.

Ajax Therapeutics is a biotechnology company developing precision therapies for blood cancers called hematologic malignancies. The company has a unique partnership with Schrödinger, Inc. to develop novel small molecules targeting cytokine signaling pathways for hematologic malignancies.

Ajinomoto is a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients and consumer food products.

Ajna BioSciences is pioneering the development of FDA-approved botanical pharmaceuticals to revolutionize the world of medicine. Our strategy encompasses a focus on select plant and fungi species with a well- established history of therapeutic use, which streamlines the drug discovery process, mitigates late-stage clinical trial risk, and propels us towards unprecedented medicinal breakthroughs. With a specialized infrastructure and industry expertise, we're strategically poised to lead and create significant value in this exciting, nascent category of pharmaceuticals. Join us as we tap into the transformative potential of nature, shaping the future of health and medicine.

Akashi Therapeutics is a clinical stage biotechnology company developing a portfolio of products for Duchenne muscular dystrophy and other rare diseases. The lead clinical asset is HT-100, and drug candidate with potent anti-inflammatory and anti-fibrotic properties that also promotes healthy muscle regeneration. The company's second clinical candidate is DT-200, a Selective Androgen Receptor Modulator (SARM), targeted to build muscle mass and strength.

AKAVA Therapeutics is developing first-in-class small molecule therapeutics that inhibit protein aggregation, inhibit enzymes and inhibit cancer for a variety of neurodegenerative diseases.

Since our founding in 2007, we’ve put tenacity and innovation to work to develop novel therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal community. Today, we are a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization.

Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs. Over 21 million adults suffer from Neuropathic Pain in the US alone†, for which opioid medication is a common treatment. Associated costs exceed $90 billion/year in the US,† and roughly 40 ‐ 70% of people do not receive proper medical treatment and are at risk for either over‐ or under‐treatment.‡ Akelos: Building New Frontiers to Address Neuropathic Pain Akelos is an innovative research-based biotechnology company founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. Akelos holds an exclusive worldwide license with Columbia University and Cornell University and is working in collaboration with Weill Cornell Medicine. Researchers at Weill Cornell University and Columbia University have developed novel compounds for the treatment of neuropathic pain, resulting in intellectual property that is jointly owned by Cornell and Columbia. Akelos has licensed this intellectual property and is developing a treatment for neuropathic pain using the novel compounds.

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco.

Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha radiopharmaceuticals for the mainstream of cancer care.

Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company’s lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.

Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world. Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, as well as local and regional operations in countries around the world. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day.

Algomedix is an emerging biotechnology company which is using the advances in precision medicine to accelerate drug discovery and development for TRP (Transient Receptor Potential) targeted therapeutics. Critical members of the large TRP superfamily include TRPA1, which is a validated target recognized by the pharmaceutical industry for the discovery and development of novel therapeutics to treat pain, inflammation, ocular and dermatological disease. Algomedix has successfully identified novel small molecules that target human TRPA1 with both high potency and specificity, and have been optimized to have excellent drug-like properties. Thus, the Algomedix compounds represent a major advance in next-generation pain killers which have no opioid related, NSAID related, or gabapentanoid adverse effects, and have been rationally designed to have no addiction or abuse liabilities. These advantages are further enhanced by a primary peripheral mechanism of action, blocking pain at its source. Algomedix possesses near-term clinical development opportunities combined with novel approaches to developing its first-in-class novel therapeutics addressing a critical unmet medical need. Algomedix's most advanced patented compound is in late-stage preclinical development and prepared to advance to clinical trials. This compound has demonstrated potent analgesic activity activity in multiple established pain models, which are recognized as the gold standards in the areas of osteoarthritis pain (OA), neuropathic pain, and chemotherapeutic-induced peripheral neuropathy. Due to the critical and fundamental role of TRPA1 in mediating the initial steps of pain signaling throughout the body, there are multiple therapeutic applications for treating chronic and acute pain in patients. In addition, Algomedix is pursuing programs developing a pipeline of novel, first-in-class molecules for other indications, which include chronic kidney disease and cardiac hypertrophy

Alida Biosciences is an early-stage, VC backed startup in San Diego focused on developing novel genomic analysis tools. The company’s technology will advance the understanding of RNA biology and provide actionable information for improving human health.

Aligen is a Pharmaceutical, Nutraceutical, and Cosmetic manufacturer that specializes in Softgels, Capsules, Tablets, Gummies, and Skincare Topical Creams.

Our strategy is to develop pharmacologically optimized drug candidates, which are first assessed in healthy volunteers and patients as monotherapy prior to their use in combination regimens designed to achieve improved treatment outcomes in patients. Our initial areas of focus are viral and liver diseases where our team can leverage their in-depth knowledge and expertise to develop potentially best-in-class combination regimens for each disease area with significant unmet medical need.

They are focused on the discovery and development of novel biotherapeutics to combat the debilitating muscle and bone loss and the loss of functional capacity, as occurs in various neuromuscular diseases, cancer cachexia, congestive heart failure, geriatric sarcopenia and frailty, as well as in other chronic diseases, for which no approved therapies are currently available.

Alixia is a medical research company that engages in developing new modalities to treat cancer, aging, and inflammation.

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

We are the pioneers of allergy solutions. Allergy is the most common chronic disease globally and it has profound impact on people’s lives. More than 500 million people worldwide live with respiratory allergies, more than 200 million people have some sort of food allergy, and more than 100 million children are living with allergic rhinitis. These numbers are only expected to increase, and as a result, the need for allergy solutions is ever-growing. For more than a 100 years, ALK has been at the forefront of long-term allergy treatment. Building on our strong heritage, we are now stepping into the next 100 years with a mission to help even more people, with more solutions, more efficiently. We call it Allergy+. ALK is a global company with production sites in Denmark, France, Spain and the United States. ALK was founded in Copenhagen in 1923 and today we employ around 2,900 people around the world. Our global headquarters is located in beautiful surroundings in Hørsholm, north of Copenhagen. Read more about ALK at www.alk.net

Founded in 1984, All American Pharmaceutical is a leading manufacturer of dietary, food and nutritional supplements. We specialize in producing private label and custom formulations for almost anything from general health and sports nutrition to anti-aging products and food products. All American Pharmaceutical has the capability to produce liquids, capsules, powders and tablets products from concept all the way to finished packaging. We are also the exclusive manufacturer and patent holders of two branded ingredients: Kre-Alkalyn® and Kre-Celezine® Formulating and producing effective, high-quality products is not as simple as mixing a few ingredients together and then dumping them into a bottle. Most people who hire a contract manufacturer don't even realize there are major differences between companies, regardless of price. Before hiring any manufacturer, you need to know what their quality standards and current certifications are, how quickly they can turn your products around and if they even have the capability to pull off your job in the first place. After all, your brand's credibility, integrity and hard-earned image are on the line. All American Pharmaceutical has been developing quality products for the past three decades. Over the years, we've listened to your needs and have responded to offer a variety of production and packaging capabilities. And we do it all in our cGMP certified, state-of-the-art 150,000 square foot facility located in Billings, Montana.

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.

Allodynic Therapeutics is a clinical-stage biopharma company engaged in developing naltrexone-acetaminophen (ALLOD-2) as an oral investigational product for the acute treatment of migraine. Both naltrexone and acetaminophen individually can simultaneously reduce physical and emotional pain, potentially enhancing treatment outcomes. Naltrexone-acetaminophen U.S. patents extend to 2037.

Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical focused on rare diseases with high unmet needs. We are developing first-in-class therapeutic peptides with multiple biological actions, including anti-fibrotic, anti-inflammatory, cell regenerative, and beneficial metabolic effects that provides development opportunities across multiple diseases. Our lead drug, ALY688ER, an extended release formulation designed for extended delivery of ALY688 throughout the body, is a potent and specific activator of adiponectin signaling pathways. Adiponectin is a beneficial cytokine produced mainly by adipose cells and which protects against obesity-associated diseases. ALY688 is the first adiponectin receptor agonist to enter human testing. Our lead indication is Duchenne muscular dystrophy (DMD), a serious rare genetic disease of boys in which muscle tissue damage due to muscle cell injury, inflammation and replacement of muscle by fibrotic tissue results in progressive loss of skeletal muscle function. In relevant animal DMD models, ALY688 reduced muscle cell death, enhanced muscle regeneration, and reduced inflammation and fibrosis, resulting in preservation of muscle strength and endurance. In addition, ALY688 has shown similar benefits across a range of other inflammatory and fibrotic conditions potentially expanding its use in additional indications.

Allyx Therapeutics is a clinical stage biotechnology company aiming to develop disease modifying therapies for Alzheimer's and Parkinson's. They are developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease.

Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have three additional medicines on the market: GIVLAARI (givosiran), OXLUMO (lumasiran) and LEQVIO (inclisiran) in partnership with Novartis). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,700 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 3 years in a row ('19-'21), a Boston Globe Top Place to Work 7x in a row ('15-'21) and one of Fast Company's Best Workplaces for Innovators for 2021.

Alopexx Enterprises works with scientists and entrepreneurs to build successful new companies. We invest in novel health care technologies at all stages of development and can serve as a lead investor or collaborate with a group of investors to advance important science. We also have the capabilities to provide management and development expertise where needed. To date, our initial investments have ranged from $1-20M. The Alopexx team consists of experts who have deep industry knowledge and technical expertise in all areas of drug development including, pharmacology, CMC, toxicology, medical and clinical operations, quality and regulatory affairs. We form collaborations with academic institutions, biotech and pharmaceutical companies to advance our portfolio companies to deliver breakthrough therapies to patients in need. Our business model is to invest and develop to an important inflection point and then partner the asset for further development and/or commercialization. Portfolio companies include: -Alopexx Pharmaceuticals -Alopexx Oncology -Alopexx Vaccine -Valerion Therapeutics -Janus Biotherapeutics -Cognoptix

Alpha-1 Biologics is a biotherapeutics company developing innovative treatments for cancers and immune deficiencies. The company is dedicated to their mission to develop patented therapeutics related to the generation of immune cells from stem cells within the body to treat immunodeficiency with disease applications including immune cell replenishment in cancer therapy, HIV/AIDS, patients with inherited deficiency of α1PI, and in the most prevalent cause of immune deficiency, malnutrition. Alpha-1 Biologics is currently testing their orally-available, small molecules in studies to determine their ability to increase the number of tumor infiltrating CD4+ T cells and coordinate with immune checkpoint inhibitors to eliminate tumors. The discoveries at the core of Alpha-1 Biologics therapeutic approach resulted from basic research conducted by Dr. Bristow and supported for many years by the non-profit research organization, Institute for Human Genetics and Biochemistry (IHGB) funded by the Harry Winston Research Foundation.

Alphazyme was founded in 2018 by Christopher Benoit, Stephana Petrino and Chad Decker. Our experienced team has a track record of success and a passion for supporting molecular biology innovators. Our mission is to be the world’s premier partner for custom, industrial-scale, molecular biology enzymes. We are enzyme development and production experts, and partner with the manufacturers of nucleic acid therapies and detection platforms to develop and produce affordable, reliable enzymes which meet the specifications of the rapidly expanding market for custom DNA and RNA molecules, genomic medicines and genetic tests. Consistent quality, scalable processes, and compatibility with regulatory requirements are the hallmarks of our business.

Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. Its lead product candidate, AB-101a, is a topical treatment for atopic dermatitis (AD), the most common form of eczema, and has completed a Phase 2a clinical trial. AB-101a has demonstrated a strong safety profile and is in development to uniquely target AD's bacterial and immune system components, making it ideal for treating infected and non-infected AD. Alphyn's AB-101 platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics with potential safety, efficacy, and regulatory marketing authorization advantages. Alphyn is based in Annapolis, Maryland, and Cincinnati, Ohio, and has a wholly-owned subsidiary in Australia. We became operational in 2020 and have raised approximately $6.7 million.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS).

AltaThera Pharmaceuticals is a specialty pharmaceutical company focused on identifying, acquiring, developing and commercializing therapies for the unmet medical needs of critical care patients and those with severe, often rare, disorders for which few effective treatments are available.

Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. We are a team with expertise in multiple areas of science and operations, dedicated to co-elevating toward our vision to bring life-changing and life-saving therapies to cancer patients. We believe in our journey, in each other, and in our ability to collaboratively develop therapies that will help end cancers. Thus, we seek the best people for our company and provide the resources they need to grow, develop, and accomplish our collective goals. We are moving forward with humility & empathy, fearlessness & resilience, with a sense of inclusion & belonging, open communication and a deep trust. And…we manage to have a lot of fun along the way!

Altesa is a clinical-stage pharmaceutical company dedicated to developing new treatments for age-old threats to human health: high-consequence viral infections. These infections are particularly severe in vulnerable people, including those with chronic health conditions, like lung diseases, as well as the elderly and many people in underserved communities. Altesa builds upon a proven, highly successful drug development platform that has already prevented countless deaths from the two most impactful pandemics of the past 100 years—HIV/AIDS and COVID-19. Our objective is to develop safe and effective antiviral medicines in simple oral dosage forms that, when prescribed for the right people at the right time, will halt the progression of infection before it becomes serious—or even prevent the infection altogether. This strategy extends the proven benefits of testing for viruses such as the flu or COVID-19, which have both caused suffering and death among vulnerable people but can be treated if properly diagnosed. Viral pathogens like these and others have plagued mankind for many thousands of years, but testing for and treating them is an effective strategy to blunt their impact and, ideally, to defeat them.

Althera is focused on development and supply of innovative patient focused medicines. Althera’s medicines are approved and available to patients in more than 35 countries worldwide. ​Founded in 2010, we are leaders in development of innovative combination medicines in therapeutic areas of Cardiology and Diabetes, and work closely with our B2B partners in making these products available to patients in geographies across the world including all major markets in Europe and Emerging Markets including Asia, Latin America and Africa. ​Our strong R&D capabilities and network of manufacturing sites enable innovative and cost effective supply of medications to improve patient health.

AltiBio, Inc. is a San Francisco Bay Area biopharmaceutical company founded in early 2017 to bring relief to people living with rare and severe diseases. The management team has extensive experience developing and commercializing orphan therapeutics. The company currently has three projects in development, with two molecules. More news will soon be coming as the company nears its next big milestone...

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. We are passionate about making people's lives better by making high quality medicines more accessible around the world. The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.

Launched in February 2024, Alys Pharmaceuticals is an innovation leader in immuno-dermatology, co-founded by Medixci and world-leading dermatology and scientific experts. Originating from the aggregation of six asset-centric Medixci compannies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. With a vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet medical need, Alys aspires to redefine the landscape of dermatological treatments.

Alyssum Therapeutics, a biotechnology company which is developing next-generation immunotherapies to modulate B cells

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company’s lead product candidate is AL001 for the treatment of Alzheimer’s and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient’s immunological system to Alzheimer’s. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com

AmberGen® is a biotechnology company and producer of Miralys™ spatial biology imaging solutions. Miralys™, also known as MALDI HiPLEX-IHC, is a new breakthrough method for targeted intact protein imaging that has unique multimodal imaging capabilities. First introduced in 2022, it has gained significant traction, including 8 of the top 10 pharma companies, as well as many of the world's premier research institutions. It is currently being used to study tissues for a wide range of diseases including cancers, Alzheimer's and Parkinson's diseases; and even COVID. Benefits include: - Drug/target co-localization on the same sample, same instrument - The ability to produce images that co-register small molecule lipids and metabolites as well as the intact targeted proteins. - The product's combination of fast, targeted, protein imaging (scan time as short as 45 min and 1cm2), ultra-high plex (10 to 100+), wide viewing area (up to 25 x 75 mm), and multi-modal capability make it an ideal technology for doing initial scans to identify regions of interest for later deep-dive analysis. - Miralys™ requires no dedicated instrument, and minimal investment to start using. It is used on MALDI Mass Spec Imaging instruments that your institution most likely already owns, such as the industry-leading instruments from our partner, Bruker Corporation.

At Ambient Biosciences, we are dedicated to being a true partner in your success. We bring the same spirit of versatility, transparency, and innovation to our customer relationships as we do to our technology. Our approach is to take the mystery out of biomolecule stabilization, making it an accessible and collaborative process that empowers you to feel confident about your products and assays.

Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.

ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held company based in San Diego, California, developing new small molecule drugs for treating neurodegenerative disease initially focused on traumatic brain injury and Alzheimer's disease. Our approach is to identify key enzymes in the brain, called proteases, which produce biologically active peptides, proteins or processes that are thought to underlie the disease. We then use those enzymes as targets for screening compounds that inhibit these proteases and thereby prevent the harmful effect caused by these peptides, proteins and processes to treat the disease. By using this innovative process, our goal is to create and advance highly-effective drug development strategies and products for treating not only traumatic brain injury and Alzheimer's disease, but other Neurodegenerative Conditions such as Huntington's disease, Parkinson's disease and MS, and recover quality of life for those patients and their families.

Amethyst provides cGMP compliant, custom, creative, and cost effective services (4Cs) for FDA regulated activities to increase its customers' profitability, ensure compliance, and promote patient safety.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Philadelphia, Pennsylvania.

Amivas (US), LLC is an Australian, Canadian, and US joint venture focused on the development, manufacturing, and commercialization of therapeutics for the treatment of infectious diseases. Amivas (US), LLC was formed in response to the urgent need for a US -based firm to assume responsibility for the manufacture and distribution of Artesunate for Injection, for severe malaria after quinidine gluconate was discontinued by the manufacturer. With FDA approval of its first commercial product, Amivas (US), LLC is proud to join the global effort to fight and eradicate malaria.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Amygdala Neurosciences is a biopharmaceutical company whose mission is to invent and develop first-in-class medicines to treat substance use disorders (SUD). Amygdala Neurosciences, headquartered in San Francisco, CA, is an independent small biopharmaceutical company founded in 2015.

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company’s product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amyndas is a pharmaceutical company developing potent complement therapeutics for inflammatory diseases and disorders based on its patented technology for modulating the complement system.

AmyriAD Therapeutics is a privately held, late clinical-stage pharmaceutical development company focused on advancing effective therapies for Alzheimer's Disease (AD). The company's leadership has a legacy of success in AD drug development and brings together decades of experience in AD with the singular goal of developing innovative treatments for this debilitating condition.

Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world's top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands - all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Anagram is a clinical stage company leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can make a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. Malabsorption syndromes and nutrient metabolism disorders prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. ANG003, Anagram’s lead product is intended for the treatment of malabsorption and exocrine pancreatic insufficiency and is a new class of broad-spectrum digestive enzyme replacement therapy.

CenExel ACT is dedicated to performing medical clinical trials to find new patient therapies in unique areas, including Japanese-and Chinese-bridging studies. Our Phase I Clinical Pharmacology Unit is a 30,000 SF, state-of-the-art, 90 beds, clinical research center, and features: Private patient rooms and ward setting, State of the art entertainment 24-hour medical coverage, 7 days a week, On-site Surgery Suite (2 Procedure Rooms, 3 Recovery Beds), Emergency Room and Intensive Care Unit located close by In the clinical trials area, we ffer investigational therapies for indications such as Migraines, Insomnia, Chronic Pain, Osteoporosis, Hormone Replacement Therapy, Diabetes and much more. We offer new and existing therapies that manage conditions where other medical therapies may have failed. Each and every CenExel patients receive the highest quality medical care. We notify the patient's primary care physician of enrollment and ongoing status and provide a full report at the conclusion of each study. To learn more about working with us as a Sponsor or CRO for your clinical trial visit CenExel.com/ACT or call 714-774-7777.

AnaSpec, a subsidiary of Kaneka Eurogentec, is a globally recognized biotechnology company that manufactures and sells custom and catalog Peptides, Fluorogenic and FRET Assay Kits, Fluorescent Dyes, Amino Acids and more, for research use, drug discovery and diagnostic use. We also manufacture custom Peptide based starting materials for GMP applications. As a trusted and long-standing provider to the biopharmaceutical and diagnostic industries, academia, and governmental institutions, we aim to empower the scientific community in their endeavors to elucidate diseases and enhance health and well-being, through our quality proteomic products and services. Our team of experts strive for excellence with honesty and transparency on behalf of our customers. AnaSpec established in 1993 is certified to ISO 9001:2015.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. The Company’s lead product candidate, ANAVEX®2-73 is undergoing four mid- to late-stage clinical trial programs for CNS diseases where no good treatment options exist, or current treatments are inadequate. These include Alzheimer’s disease (Phase 2b/3) and Parkinson’s disease dementia (Phase 2), which are neurodegenerative diseases that are on the rise due to aging populations in developed nations. Additionally, Anavex has two ongoing Phase 2 trials for Rett syndrome, a neurodevelopmental disease that mostly affects young female girls. Anavex has received Orphan Drug Designation from both the FDA and EMA for Rett syndrome. ANAVEX®2-73 has potential to treat other CNS disorders, given its ability to restore upstream cellular homeostasis. Anavex has received funding from Rett Syndrome Foundation, as well as Michael J Fox Foundation supporting Anavex’s studies. Anavex has identified a novel biomarker signature (genetic variants) that have potential to determine which patients will benefit the most from ANAVEX®2-73, which targets the Sigma-1 receptor (SIGMAR1), a natural cell signaling pathway that is activated to restore cellular homeostasis.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

ANEUVO® is a Platform and Therapy Development company focused on treating chronic injuries and conditions that have not been curable through traditional pharmaceutical approaches. ExaStim™ is a non-invasive neuromodulation system developed by Aneuvo that has received FDA Breakthrough Device Designation for treating spinal cord injury.

AngioDesign is developing the first truly-novel, next-generation combination inhibitors (C-domain ACE, C-domain ACE/NEP, N-domain ACE) with the potential to treat a number of the most important conditions impacting human health today, including heart failure, hypertension and fibrosis. Cardiovascular disease is the single most common cause of death in the world. AngioDesign’s drug discovery platform is focused on the rational design and development of improved, next-generation drugs for proven disease targets and its initial focus is on the development of inhibitors of angiotensin-converting enzyme. AngioDesign uses a lean management approach in its quest to optimize this effort.

AnHeart Therapeutics is a clinical-stage global biopharmaceutical group company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for the first-line TKI-naïve and second-line TKI-pre-treated patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). The Company's pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the successful launch of our lead asset, Purified Cortrophin® Gel, strengthening our generics business with enhanced research and development capability, innovation in established brands and leveraging our U.S. manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.

Ankyra is developing a novel approach for cancer treatment called Anchored Immunotherapy, promoting prolonged immune activation locally while limiting systemic toxicity.

Annam Biosciences is a biotechnology company that focuses on developing transformative drug delivery technologies and drug candidates.

At Annovis Bio, Inc., we are pioneering a novel approach to fighting chronic and acute neurodegeneration, offering new hope against the largest unmet need of our aging population - Alzheimer’s and Parkinson’s diseases. Our diverse pipeline also targets such neurodegenerative conditions as traumatic brain injury (TBI), stroke, Down Syndrome, Huntington disease, and mental illnesses. Our lead compound, buntanetap, is a small, once-daily, orally administered, brain-penetrant inhibitor of neurotoxic proteins. The biological activity of buntanetap has been evaluated in 19 animal studies conducted in leading institutions such as the Karolinska Institute, Columbia University, and Harvard University. We have also conducted seven clinical studies in over 1,000 people, which consistently showed that buntanetap is safe and well-tolerated. Moreover, buntanetap has shown the ability to normalize levels of several neurotoxic proteins – APP, tau, aSYN – to those seen in healthy volunteers. In our late-stage trials, buntanetap significantly improved cognitive functions (ADAS-Cog11) in patients with mild Alzheimer’s disease, halted cognitive decline in Parkinson’s patients, and improved motor and non-motor Parkinson’s-related functions (MDS-UPDRS) in several disease subpopulations. We are currently in the process of submitting our latest data to the FDA and planning two pivotal Phase 3 studies—one for Alzheimer’s and one for Parkinson’s. We believe that buntanetap holds the potential to be the first drug to address the underlying mechanisms of neurodegeneration, heralding a new era in the treatment of these debilitating diseases.

Anodyne is a venture-backed, clinical-stage biotech company focused on simplifying chronic care for all stakeholders. We specialize in the transdermal delivery of multi-milligram doses and complex formulations, enabling easier access to both existing therapies and emerging large molecule treatments. The HeroPatch, our proprietary technology represents a breakthrough in drug delivery. By transdermally delivering large molecules, it enables tunable pharmacokinetic profiles, new formulations using APIs in dry form, room temperature stability, and combination therapies of next-generation therapeutics. Our product pipeline is dedicated to addressing the unmet needs of chronic diseases, with an initial focus on obesity. We are committed to delivering innovative solutions that significantly impact patients' lives. Anodyne is actively expanding its pipeline through both internal clinical development and strategic external partnerships, maximizing the commercial potential and clinical impact of our advanced drug delivery platform.

Founded in 2002, ANP Technologies, Inc. is an emerging nanobiotechnology company with a major focus on design, development, and marketing of innovative technologies. ANP Technologies, Inc. is a nanobiotechnology company with cutting-edge technology platforms focused on: • Specialty CRO for biological drug R&D • Biodefense and homeland security • Home/point-of-care diagnostic systems • Nanoencapsulation and targeted drug delivery and therapy

At Ansa Biotechnologies, we’re developing a way to synthesize DNA that will accelerate innovation in medicine, agriculture, and industrial biotechnology. Our fast, clean, and accurate enzymatic DNA synthesis process can produce gene-length molecules directly, overcoming bottlenecks of traditional DNA synthesis methods. We envision a future where our technology empowers scientists to develop solutions for the world's biggest problems in health and sustainability. Note that Ansa does not conduct any employment discussions via LinkedIn. All official Ansa career openings are exclusively listed on our website careers page.

Ansella Therapeutics is a specialty pharmaceutical company that leverages biomimetic sciences to develop novel therapeutics that improve healthcare outcomes.

Ansun Biopharma is a late-stage clinical development company dedicated to saving the lives of vulnerable patient populations through the creation of first-in-class biologics. Our lead product, DAS181, is a multi-function sialidase fusion protein for host-cellprotection in respiratory virus infection, including parainfluenza, influenza and COVID19,. We are also advancing several additional programs in oncology and autoimmune diseases using our sialidase platform technology.

Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole cell engineering reconstructing complex molecules in yeast to bring to market next generation plant inspired medicines. Antheia’s team of scientists and technologists is headquartered in Menlo Park, California. For more information, visit www.antheia.bio.

Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. We aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV. Our lead programs are in clinical trials in high grade anal intraepithelial neoplasias (AIN 2,3) and high grade cervical intraepithelial neoplasias (CIN 2,3). The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva’s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.

Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in the San Francisco Bay Area. We are advancing our product pipeline of improved cytokines (Exenokines, Mableukins etc) and tumor-targeting antibody drug conjugates. Our lead product, Exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. We specialize in the discovery and development of optimized immunotherapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.

Apollomics is an innovative biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.

Aponia Laboratories, Inc. was founded by Robert Boolbol, M.D. and Kenneth Corroon in 2010 to develop and introduce a safe and over-the-counter pain mitigation products.

Get the professional care you deserve when you visit our ARC walk-in medical clinic. We specialize in treating acute illnesses and injuries without you having to make an appointment. You will receive the highest quality diagnosis with safe and effective treatments in a timely manner. We provide accurate and prompt lab work on site to ensure that you get the most appropriate treatment. You can also act as an important part of our research by volunteering as a study participant. ARC of Arkansas conducts Phase II-IV Clinical Trials, Registries and Health Outcome Studies which are aimed at finding new and better treatments for various medical conditions and diseases.

Applied Therapeutics is a clinical-stage biopharmaceutical company that uses our novel drug-development approach to create transformative, life-changing treatments for the patients who desperately need them.

Aprea Therapeutics Inc., (NASDAQ: APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics to reactivate the mutant tumor suppressor protein p53, the most commonly mutated gene in cancer

APTAGEN Labs is a biotechnology company offering aptamer and aptabody custom-based services to replace antibodies in research, diagnostic platforms, drug discovery and therapeutics. Aptagen was formed in 2004. Operations began in 2006. Aptagen is located in Jacobus, PA, a suburb of York, beautifully surrounded by Lake Redman and conveniently situated off of Interstate 83. The facility is a forty minute drive from Johns Hopkins University and Hershey Medical Center.

Through our drug development expertise in brain & CNS disorders, we have developed a unique medicinal chemistry platform to discover novel product candidates. The compounds we have discovered work through modulation of NMDA receptors to avoid caustic effects associated with over-activation or full inhibition.

Biologics

Aquavit Pharmaceuticals, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. We focus on personalized medicine to improve patient health and to maximize the efficiency of the medical community. At Aquavit Pharmaceuticals, Inc., we combine this strategic focus with a modern, diverse approach that enables us to pursue new specialty areas with significant unmet needs. Science personalized. Healthcare modernized.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.

Drug discovery remains an expensive and time-consuming process. Promising compounds proceed through clinical trials only to have many fail before FDA approval. Aracari Biosciences aims to simplify this process by more accurately and efficiently evaluating promising drug compounds in a human tissue-on-a-chip model prior to clinical trials. Our​ proprietary, Vascularized Micro-Organ (VMO) platform is the first to contain a 3D, perfused network of living, dynamic human blood vessels that deliver nutrients and drugs directly to tissues just as in the body. Ask about our oncology models that incorporate multiple human tumor types within the vascularized tissue or our blood-brain barrier model for testing trans-barrier transport of drug compounds targeting the brain.

We have invented a novel enzymatic method for synthesizing noncanonical amino acids (ncAAs) also called unusual or unnatural amino acids. Our proprietary approach enables over 100 ncAAs to be synthesized with perfect enantiopurity in just a single step, with water as the only byproduct. To learn more, visit us at www.aralezbio.com Aralez Bio is a proud member of Cyclotron Road.

Arbor Assays is the first employee-owned life sciences company and is dedicated to advancing scientific discovery by providing innovative and reliable assay solutions. Our mission is to equip researchers and scientists worldwide with high-quality scientific tools and support their objectives with unparalleled customer service. Arbor Assays strives to be a trusted partner to our customers through our commitment to quality, integrity, and collaboration. As employee-owners, we are driven not by investor demand, but rather by a shared sense of responsibility to each other, our customers, our community, and our planet.

Archer Pharmaceuticals, Inc. (Archer) was founded in 2008 and specializes in drug discovery for Alzheimer’s disease and other dementias.

Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. We are an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs. We are located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub. Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus is an ambitious undertaking, and we fully expect our company to become a force in the discovery, development and commercialization of novel therapies for the treatment of cancer. Our employees enjoy operating in an exceptionally dynamic and cooperative environment in which the “rule book” has not yet been written.

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team’s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis'​ combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Community Guidelines: https://rb.gy/07ltg3

Ardigen is a bioinformatics company that specializes in AI-driven solutions for drug discovery and precision medicine.

Areteia Therapeutics is a clinical stage biotechnology company committed to putting respiratory patients in better control of their disease—and back in control of their lives. The company's purpose is to develop and deliver novel inflammation modulating therapies to improve the lives of patients with respiratory diseases. Areteia Therapeutics is dedicated to advancing the treatment of respiratory diseases, including asthma and eosinophilic asthma, through innovative research and development.

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

Argon AI is a platform that allows biopharmacy and life sciences experts to conduct complicated, data-driven operations. They help life sciences companies automate their data-intensive workflows with unprecedented AI.

Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR).

Arisan Therapeutics Inc. is a biotechnology company based in San Diego CA committed to the discovery and development of broad spectrum orally active small-molecule anti-infectives. Current programs include a number of antiviral and antibacterial discovery projects.

ARIZ Precision Medicine is pre-clinical stage company aiming to selectively target and destroy early-stage drivers of cancer, such as the deregulated PRDM genes and proteins that were previously deemed “undruggable”. ARIZ set out to prove that cancer cells with PRDM abnormalities could be individually targeted and destroyed without harming normal cells by utilizing knowledge of the PRDM gene family, proprietary siRNA constructs and innovative drug delivery nanotechnologies to target these cancer cells. Proof of principle studies confirmed that this approach selectively killed multiple types of cancer cells (breast, colon, lung, myeloma, etc.) thus ARIZ is continuing in the development of new drug candidates for cancer by pushing these products to testing in animal models of cancer. This will give ARIZ compelling data and intellectual property to share with pharmaceutical companies and, thus, enter into strategic partnerships to take our products to the clinic and then to market. Ultimately, through these efforts, ARIZ intends to cure cancers in a way that preserves a patient’s quality of life and avoids the harmful and adverse effects of current therapies. ARIZ is located in Davis, California and benefits from the combined knowledge of a board of experts in PRDM genes, drug delivery and drug development.

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

ARMGO is a privately owned, venture-backed, biotech company that is developing small molecule drugs that repair leaky Ryanodine Receptor (RyR) calcium channels associated with human diseases. Our primary focus is on two orphan diseases: the life-threatening cardiac disease Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and the severe muscle disease RYR1-Related Myopathy (RYR1-RM). These two conditions occur due to genetic mutations in the RYR gene: RYR1 in RYR1-RM, and RYR2 in most CPVT cases. ARMGO’s molecules, termed Rycals® are designed to repair leaky RyR channels. Since the cause of the symptoms is abnormal calcium leak due to these mutations, Rycals hold the promise of disease-modifying therapy for these two orphan genetic diseases.

AROG Pharmaceuticals, Inc. was formed to expedite and streamline the transition of early stage molecules into areas of unmet therapeutic needs. We are committed to scientifically validated drug development in collaboration with like-minded investigators and institutions.

Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.

At Arrivo, we strive to set a new standard in drug development that starts with the selection of drug candidates and runs throughout clinical development. Our approach and decision-making has delivered a history of excellent returns and product successes that makes us the trusted partner for industry and investors.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Was SilverBack Therapeutics, merged with ARS Pharma in 2023 ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including food, medications, and insect bites. The company was founded in 2015 and is based in San Diego, California.

Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T-cell activation. Specific control over T-cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.

ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

Arthrosi Therapeutics is a leading clinical-stage biotech company dedicated to advancing therapies for gout disease. Our proprietary oral drug candidate, AR882 which is currently in clinical Phase 3, has demonstrated unprecedented sustained urate lowering in gout patients and reduction of tophi, showing exceptional potential to treat millions of patients suffering from gout and tophaceous gout. At Arthrosi Therapeutics, we are committed to transforming the treatment landscape and improving the lives of patients worldwide.

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG

Arzeda combines protein design, pathway design, HT screening and strain construction to create and improve designer fermentation strains for virtually any chemical. One example of their work is indeveloping new and improved enzymes to make rare sugars, natural sweeteners,and other oligosaccharides.

Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

ASCEND Therapeutics US, LLC is a specialty pharmaceutical company concentrating on women’s health. With a century of innovation originating with our parent company, Besins Healthcare, ASCEND Therapeutics continues to attain high standards in commercial and product development. ASCEND THERAPEUTICS U.S., LLC is a pharmaceuticals company based out of 15 Mt Kemble Ave Morristown, NJ 07960

Ascletis is an innovative R&D driven biotech listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.

Founded in 2018, Asegua Therapeutics LLChas launched an authorized generic of EPCLUSA®(sofosbuvir/velpatasvir) and an authorized generic of HARVONI®(ledipasvir/sofosbuvir).

At Asha Therapeutics, we are leveraging our expertise in computational chemistry and neurobiology to develop novel therapeutics that enable the re-engineering and restoration of neurological function. Our lead assets demonstrate efficacy in both human cells and murine models of neurodegenerative diseases including Parkinson’s Disease, Stroke, Alzheimer’s Disease, ALS, and Multiple System Atrophy.

Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.

We are a pediatric rare disease pharmaceutical development company. Asklepion Pharmaceuticals, LLC focuses on the discovery, development, and commercialization of pharmaceutical products for pediatric patients with few therapeutic options, due to the rarity of their conditions. Our pipeline currently focuses on rare and critical diseases in children.

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle.

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company’s pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

Developing Novel Therapies for Multiple Sclerosis

Astute Medical is a healthcare company that specializes in identifying and validating unique biomarkers to rapidly assess high-risk acute conditions and diseases, supporting healthcare professionals with useful clinical tools.

Atacama Therapeutics is a dermatology company focused on advancing treatment for skin and musculoskeletal diseases. The company's pipeline includes AT-5214, a small molecule drug for the treatment of malignant hypertension.

We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. It also develops AT-787 which is under phase 2 clinical for the treatment of hepatitis C virus; AT-752 which is under phase 2 clinical trial for the treatment of dengue; and AT-889, AT-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. The company was incorporated in 2012 and is based in Boston, Massachusetts.

Atengen is developing drugs that specifically target the tumor blood vessels of most solid tumors. The long-term goal is to develop a new generation of drugs that can be used in combination with existing cancer therapies to improve patient outcomes.

Athens Research and Technology, Inc. (ART) is a dynamic life science company and recipient of the Globe Award as Georgia's 2022 Exporter of the Year. Since our founding over three decades ago, we continue to proudly support the life sciences industry in the advancement of essential medical diagnostics and therapies. ART is renowned for defining the industry standard for native protein purification. We specialize in producing natural human and animal proteins critical to academic research and manufacturing in the Clinical Diagnostic, Cell Culture Media, and Standards/Calibration industries. Our custom purification programs support our long-standing distinguished industry partners as well as our growing base of inspired customers. Since 1986, ART products have been sought after by prominent academic researchers and biotech companies for high-impact research published in Nature, Science, & Cell journals. ART proteins have been crucial for Alzheimer's, Cancer, Cardiac, Pulmonary, and Covid-19 research. Envisioned by local physicians and a university of Georgia researcher, ART was one of the first Life Science start-ups to launch from the University of Georgia incubator. Since our inception, we have served as a model for success to many subsequent companies. We are committed to People, Purpose, & Proteins. People are at the core of our belief system. Our culture continues to attract great talent, developing the next generation of industry-leading Protein Chemists. Purpose is ingrained in our being, keeping quality proteins at the forefront of research for the world's most complex medical challenges. Our purpose overflows into the Athens, GA, community as we ensure the health and strength of our neighbors and the growth of our local economy. Proteins are the core of our success. After 36 years, our company holds a breadth of knowledge of proteins and purification processes, allowing us to purify even the most complex and least abundant proteins in the human body.

At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer’s, so that patients can regain their memories, lives, and family relationships.

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for Inflammatory Bowel Diseases, lupus, and cancer. The company is focused on developing precision therapeutics for novel & specific subtypes of patients.

Founded in 1987, ATL, A Bureau Veritas Company, is a Scientific Sourcing Solutions Company. For more than 30 years, we’ve exceeded the highest expectations of the world’s most demanding customers in the Consumer Products, Pharmaceutical and Medical Device industries. ATL, A Bureau Veritas Company, has become a recognized leader in creating innovative sourcing solutions across the entire product life cycle, from discovery through commercialization. Our services range from standard rules-based testing to operating and managing entire scientific functions. We’re experts in the field of scientific sourcing. Across all levels of complexity, oversight and location, we transform cost-saving measures into strategic solutions. We can elevate your existing proficiencies and resources — all while protecting the critical continuity of business, knowledge and talent. Our capabilities include: Analytical Chemistry, Engineering, Life Science, Product Performance Testing, Product Safety and Regulatory, and Quality Assurance. At ATL, A Bureau Veritas Company, our unique solutions help maximize readiness, efficiency and productivity for our clients. We are committed to continue making “exceptional our ordinary” while delivering the science that makes life better. Careers At ATL, A Bureau Veritas Company, we don’t just do the science, we have the opportunity to transform organizations. We need people who want to grow with us and contribute directly to our clients’ success. As scientific sourcing experts, the largest and most respected companies in the world ask us to create innovative solutions to big problems. We have more input and influence, so we can have a significant impact on brand-name products and visible projects. And you can play a bigger role.

Developed a proprietary platform that holds the potential to discover novel structure targets across the transcriptome and for the design of RNA-targeted small molecules, RNA-based medicines and RNA tools.

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Aucta Pharmaceuticals, Inc. (AUCTA, Latin-improved, enhanced) is a technology-based company focusing on the development and commercialization of Branded Specialty Products and Technology Platform-based Niche Generics. Aucta is a pharmaceutical company creating enhanced products from proven molecules using the 505(b)(2) regulatory pathway. Through innovation, Aucta is creating new therapeutics, including new dosage forms, new dosing regimens, and new indications. Aucta has a clear therapeutic focus in CNS disorders, Ophthalmic, and Inhalation Therapy. We are committed to being patient-centric by continuously bringing improved forms of proven molecules into the marketplace. Aucta has operation in both New Jersey, U.S. and Shanghai, China. Our mission: Enhanced products from proven molecules!

Augmenta Bioworks discovers new therapeutics by harnessing the most powerful force in the fight against disease: natural human immunity. Our technology pinpoints the protective immune response of individuals and translates discoveries into therapies.

Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid tumors and hematological malignancies.

Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve. CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people. We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry platform to develop novel, small molecule therapies that harness the regenerative power of the human body, with an initial focus on high unmet need areas neuropsychiatry, neurodegeneration, and neuroinflammation. Our pipeline is led by ABX-002, a centrally-penetrant thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression.

Auxilius Pharma is an emerging specialized pharmaceutical company with a focus on further developing and optimizing medications well established in some markets but not in the others, for the benefit of patients and to address major unmet needs in an increasingly cost conscious health care market environment. We are a versatile team with multifunctional healthcare experience in both the US and EU. We feature diverse backgrounds and strong core competencies in pharmaceutical marketing, drug development, pharmacology, health care management, corporate finance, and asset management.

AVACEN Medical is a healthcare technology company that specializes in noninvasive medical devices for pain management, offering drug-free alternatives for various chronic and acute conditions.

Avalo Therapeutics Inc. (Name changed from Cerecor Inc.) is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. We are a Delaware corporation, organized in April 2011 in partnership with various laboratories and research institutes at Johns Hopkins Medical Institute ("JHMI"​). Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. We acquire rights to early stage therapeutic technologies ("assets"​) from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.

Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis

Avammune Therapeutics is a drug discovery company focused on the development of novel immunotherapeutics to address high unmet medical needs. Our research is driven by the science that have a potential to create a significant difference on the disease platform. Our expertise lies on developing small molecule drugs that can be administered systemically and can potentially overcome the issues faced by the currently available therapeutics for cancer and immunological disorders. We work with experts in disease biology to achieve this goal which aims at improving the lives of patients significantly. Our research efforts has led to successful completion of projects in the immunoncology space.

AvantGen is a biotechnology company dedicated in accelerating antibody-based therapeutics for their scientific partners by using innovative platforms. Based in San Diego, the fun and collaborative team is steadfast in this pursuit.

Avazyme, Inc. a contract research solution provider, offering field and laboratory testing, product development, and expert consulting services to the agriculture and food industries. Avazyme's comprehensive services include food safety analyses for contaminants, pathogens, allergens, food quality and nutrition analysis, genetic trait testing, product safety, FDA Menu Labeling, pesticide residues, mycotoxin analysis, specialized studies for regulatory submission data packages, and a full spectrum of testing for product safety and product quality related to Industrial Hemp. Avazyme provides fast and reliable answers to ensure product safety and high product quality for consumable food, feed, cosmetics, nutraceutical Avazyme also offers comprehensive laboratory and "​in-brewery"​ services to craft breweries and local hops growers and maltsters. Most recently, Volker and his Avazyme team have been a strong supporter and testing partner for the fast-emerging Industrial Hemp Industry in North Carolina and the entire East Coast

Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). FBIO owns a controlling number of voting shares of ATXI. Invagen entered an agreement to purchase ATXI if certain conditions are met, including approval of IV tramadol before April 30, 2021, but Invagen has indicated that due to the Covid epidemic, it can terminate its purchase agreement to acquire ATXI.

Avenzoar Pharmaceuticals is a start-up pharmaceutical company founded in 2016. Avenzoar is specialized in developing cancer drugs aiming at targeting and

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing the next generation of oncology therapies for patients.

AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering and developing targeted therapies designed to provide substantial impact in patients’ lives with clear unmet medical needs. AVEO’s proprietary Human Response PlatformTM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. For more information, please visit the company’s website at www.aveooncology.com.

Avet Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Avet Pharmaceuticals provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions. Our global supply chain network is built around centers of manufacturing and scientific excellence to provide you with the highest level of quality, safety, value and service in generics. Our drug portfolio consists of numerous products across a wide range of therapeutic categories, including: cardiovascular, oncology, metabolic disease, anti-infective, infusion and pain management. We are focused on widely utilized, established products as well as niche, high barrier-to-entry products that have limited competition and long life cycles.

Avicenna Biosciences was founded to solve the intractable challenges that previously stopped drug candidates in their tracks. We have created an ML-driven medicinal chemistry platform that makes Lead Optimization faster, cheaper, and more successful – transforming sub-optimal development candidates into life-saving drugs. The platform has seen rapid success in discovering the first orally available, CNS-penetrant ROCK inhibitors for the treatment of neurodegenerative diseases, with IND-enabling studies initiated just one year since the program kicked off.

AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical trials. The company's lead drug AVM0703, an innovative formulation of dexamethasone, when given at suprapharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 triggers the production and release of endogenous gamma delta+ Natural Killer T cells and could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology. The company is committed to developing products that improve outcomes without additional suffering because side effects from treatments should never be worse than the diseases themselves.

Axial Therapeutics™ is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurodegenerative diseases.

AxisPharm is a San Diego based antibody drug conjugate (ADC) linker product and service provider. At AxisPharm, we focus on manufacturing novel ADC linkers, site specific molecular probes and advanced biochemical reagents. We also provide a variety of bio/chemical services worldwide, including custom synthesis and integrated drug discovery services.

Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibitory neurotransmission within the brain, by translating breakthrough discoveries spun out from Boston Children’s Hospital, Harvard and Laval University. The company has built a proprietary KCC2 discovery engine, based on several years of world-leading know-how, to become the leaders in this potentially blockbuster drug space. Axonis’ lead development candidate, AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain. Axonis recently closed a $115 Million Series A financing co-led by Cormorant Asset Management and venBio Partners with significant investments from Sofinnova Investments, MRL Ventures Fund (Merck & Co., Rahway, NJ), Perceptive Advisors, Solasta Ventures and Lumira Ventures. Axonis is grateful for grant awards received from NIH, DoD, Wings for Life, MLSC, Praxis SCI, CURE Epilepsy, ISSNL and SynGAP Foundation. The company is headquartered in Boston, MA. For more information, visit www.axonis.us.

Our Mission: For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company’s product candidates, AL101 and AL102, were licensed into Ayala from Bristol Myers Squibb. Our lead product candidate AL101 is currently in Phase 2 clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma, for patients bearing Notch-activating mutations. Our second product candidate AL102 is being developed for the treatment of desmoid tumors. In addition, we are collaborating with Novartis to develop AL102 for the treatment of multiple myeloma in combination with Novartis’ B-cell maturation antigen (BCMA) targeting therapies. The company is based in the US and Israel.

AyuVis is a start-up biopharmaceutical company focusing on developing New Molecular Entities (NME) as immune modulating, anti-microbial, and anti-inflammatory drugs. Our pipeline of drug candidates is based on a new platform technology that modulates macrophages in the innate immune system to restore balance while fighting both infection and inflammation. Stimulating these macrophages produces a rapid therapeutic response throughout the body as we have seen in our strong preclinical data. This is unlike any existing immunotherapies today - immunotherapies which in total have annual sales of $70B. Because the antimicrobial action of our compounds is through the activation of phagocytosis, the development of multidrug resistance is not anticipated. Our goal is to save and improve lives, reduce hospital costs, & provide an effective treatment to diseases like BPD, VAP, and ARDS with no adverse side effects that are seen with the current alternatives. Our lead candidate is Orphan Drug and Rare Pediatric Disease Designated by the US FDA for the prevention of bronchopulmonary dysplasia (BPD) in at-risk preterm infants. BPD is a rare pediatric lung disease in preterm babies caused by inflammation from supplemental oxygen required for survival in the NICU and is the second leading cause of death in preterm babies. An average of 112 preterm babies die per month in the US due to the lack of an effective therapy and survivors require ongoing care. AyuVis has 2 patents approved by the USPTO and more countries which include composition of matter of our compounds, methods of use, formulations, and more.

Azome Therapeutics is an early-stage drug discovery company focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases. Our lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.

Azora Therapeutics is a pharmaceutical development company developing novel therapies for serious autoinflammatory diseases like hidradenitis suppurativa.

Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of patients with underserved conditions. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients.

Bantam Pharmaceutical is a drug discovery company harnessing the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial dynamics, Bantam is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. Bantam is currently pursuing an IND application for Its lead candidate, BTM-3566, in B-cell malignancies. About BTM-3566 BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566’s anti-cancer mechanism of action is unique from any other therapeutic, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is currently underway and will be completed by Q1 2022.

We're a leading global eye health organization that is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, we have a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries.

Bay BioSciences provides high quality human biomaterials, fresh frozen human tissues, FFPE Tissue Blocks, bio fluids like whole blood from diseased and normal subjects, serum, plasma and other blood products. Bay BioSciences specializes in characterized and documented human bio-specimens for research and development projects and is a leading global biobank offering vital products and services facilitating breakthroughs in translational medicine, genetics, drug discovery, biomarker research, companion and molecular diagnostics.

The company providesservices inbioanalytic, molecular and cellbiology, in vitro and in vivo pharmacology.The company's capabilities include assay development and in vitro/in vivo pharmacologystudies forantibodies, small molecules, siRNAs, proteins, and gene therapy products.

BCN Biosciences is a privately held pharmaceutical company with core competency in oncology drug development. BCN is currently developing novel small molecule drugs for the treatment of cancer.

Beech Tree Labs strives to address unmet medical needs affecting the life of millions of people. For more than 15 years, we have been developing formulations that target the body’s signals to restore a healthy equilibrium.

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. On November 14, 2024, the company announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible.

Belhaven Biopharma is developing a portfolio of dry powder nasal medicines to provide convenient, safe, and rapid treatments in emergency situations

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, the materials we wear, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the development of breakthrough products and accelerate time to milestone and market. Come help us bring modern software to modern science. https://www.benchling.com/careers/

Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS. The company’s lead compound, BXQ-350, is a novel S1P modulator. With our highly experienced biotech leadership team and expertise in Oncology, we are urgently progressing our pipeline to develop life-changing oncology therapies on our path to becoming a leading biotech/pharmaceutical company.

Beyond Air Inc. is a commercial stage medical device and biopharmaceutical company focused on harnessing nitric oxide therapy. The company is built on a legacy of innovation and is revolutionizing nitric oxide therapy. Beyond Air Inc. has experience and leadership that go beyond, with a team of industry professionals dedicated to advancing medical treatment. For more information, visit https://www.beyondair.net/

BeyondSpring Pharmaceuticals is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes. The Company is developing treatments in two of the world’s largest markets, China and the United States. BeyondSpring’s first-in-class lead asset plinabulin, a selective immunomodulating microtubule-binding agent, is being developed as a “pipeline in a drug” with potential to be an anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). In the DUBLIN-3 Phase 3 study, the plinabulin and docetaxel combination met the primary endpoint of extending overall survival, compared to docetaxel alone in 2nd/3rd line non-small cell lung cancer (EGFR wild type). In addition, the plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data, for which it received Breakthrough status in the U.S. and China. Plinabulin is also currently being studied as part of other immuno-oncology (IO) combination regimens that include radiation and/or checkpoint inhibitors for the treatment of a number of cancers. Lastly, BeyondSpring also has three preclinical IO assets and majority ownership in its subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

What We Do We focus on rapid, easy-to-use, lateral-flow immunoassays. We develop the crucial reagents, such as gold sols, gold conjugates, gold ribbon, etc. that are the backbone of any high-performance lateral-flow device. Superior reagents, coupled with our development and manufacturing expertise, yield superior assays. BioAssay Works, LLC powers the development of the finest rapid immunoassays. Utilizing our high sensitivity concentrated gold sols, high-performance gold conjugates, and our patented lateral-flow test platform, BAW develops and manufactures rugged lateral-flow tests that rival the sensitivity of ELISA. These tests can be read visually for quick positive/negative results or with simple instruments for more quantitative results. BAW offers a growing line of products that enable researchers and assay developers to create their own rapid assays. In addition, we are the assay-development partner-of-choice for both early-stage and established companies. We have the capability to manufacture and package your rapid assay, regardless of the volume required. BAW has developed a wide variety of assays for our clients, including assays for: Disease biomarkers In-process testing of pharmaceutical products Food allergens and agricultural targets Pathogens and toxins Veterinary applications Characterization and quantification of monoclonal antibodies

We provide you with the best experts in the biopharma industry. Through our flexible, consultative approach, we'll align you with professionals with the expertise you need when you need them the most. From early clinical and device development to the post-market phase, we help you bridge your expertise gaps.

Biocatalysts is a biotechnology company producing speciality enzymes at commercial scales for a variety of industries. Biocatalysts has used its wide range of technical, commercial and regulatory capabilities to develop #BiobasedValue for our customers. Established in 1983, Biocatalysts has been a member of the international BRAIN Group since 2018. Next to first-class research and development services for industry customers to create bio-based products and processes, the Group distributes specialty ingredients, like enzymes or bioactive natural products. Own fermentation and production facilities in Continental Europe, UK and the US, together with the associated biotechnological solution competency complete the value chain within the BRAIN Group.

BIO-CAT provides the very latest enzyme technology and custom formulations. Founded in 1988, our extensive range of products, from single-to-multi-enzyme blends, service various industrial, food, agriculture and other commercial markets. BIO-CAT is an FSSC 22000 certified facility in Virginia featuring state-of-the-art laboratories for scientific research, product development and on-site quality testing to better serve customers. BIO-CAT Microbials is an innovator in the field of biological solutions for a broad range of emerging and existing markets and industries. BIO-CAT Microbials is a GMP certified facility and a division of BIO-CAT, utilizing the latest enzyme technology in combination with microbes to produce products that are pioneering, more effective and of the highest quality for our customers’ applications.

Biocidium’s primary focus is the development of antibiotics to treat serious multi-drug resistant (MDR) gram-positive and gram-negative bacterial infections. Biocidium maintains strong antifungal and oncology programs and continues to build positive results in areas of skin treatments including psoriasis, acne, shingles and eczema.

BioCorRx Pharmaceuticals is a subsidiary of BioCorRx Inc. (OTCQB: BICX). The company was envisioned and setup with the aim of providing new options for Medication Assisted Treatment (MAT) for the treatment of substance use disorder. We are committed to developing treatments for opioid/alcohol use disorders as well as other related disorders. Our team of experts and industry leaders have a passion for helping individuals suffering from substance use disorder and to enable the medical professionals who can treat them. Our lead product candidate is BICX104; It is a long-acting naltrexone implant that can last several months and is being developed for opioid and alcohol use disorders. For product candidate updates please visit biocorrx.com.

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world. As world leaders in structure-guided drug design, we draw on the strengths and expertise of all our colleagues—from those of us in the field or behind the scenes in our labs, to others based in home offices and around the globe. To view our LinkedIn community guidelines, please visit bit.ly/BCRXGuidelines.

BioCurity Pharmaceuticals Inc. (“BioCurity”), is a biopharmaceutical company with a mission to positively transform radiation therapy for cancer patients, by addressing the global unmet need for an effective treatment to prevent toxicity from radiation therapy (radiation dermatitis). Approximately 6 million of the 18 million people who will be diagnosed with cancer every year, will receive radiation treatment. The lack of an effective treatment for the adverse side effects associated with radiation therapy represents a substantial market opportunity, but most importantly, a chance to help better the quality of life for cancer survivors around the world. BioCurity’s patented technologies and drugs in their pipeline have the potential to significantly reduce radiation toxicity for newly diagnosed patients as well as the millions of cancer patients who continue to receive radiation as a part of their ongoing treatment for cancer.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.

BioGX develops molecular products and provides partner-specified formulation and manufacturing services for molecular reagents on a platform of a partner’s choice. The company applies its proprietary platform-agnostic reagent technology to offer products and contract services across a variety of real-time PCR and Next Generation Sequencing platforms.BioGX SARS-CoV-2 Reagents for the BD MAX System - EUA 4/2020

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

Pioneered by accomplished business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide. Leveraging advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation, this biotech company is committed to optimizing the process and technology around viable human organ replacement, and making it a safe, accessible, commercially viable, and cost-effective reality.

Biolink LifeSciences is a premier contract research organization offering a comprehensive range of services including synthesis, characterization, formulation development, and analytical services for small to large molecules for nearly all dosage forms. Our strength resides with our highly experienced team in synthetic chemistry, analytical method development & validation and formulation development to solve difficult problems.

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer. As a result of BMI’s elucidation of “Deceptive Imprinting,” a mechanism of antigenic variation used by microbial pathogens and cancer cells to evade the host immune system, BMI developed “Immune Refocusing Technology” to circumvent such evasion mechanisms. Through the application of IRT, BMI strives to: (1) generate vaccines against pathogens for which no effective vaccine exists and (2) improve upon current strain-limited or serotype-limited protection of commercially available human and veterinary vaccines. IRT is able to alter the natural antigenicity and immunogenicity of targeted protein antigens making it a valuable tool to induce and select monoclonal antibodies. IRT can also be utilized to immune dampen therapeutic proteins and biologics to improve biological half-life and safety profiles.

ABOUT Biologics Consulting is a complete FDA regulatory and product development consulting firm for cell & gene therapy, biologics, pharmaceuticals, and medical devices. In the three decades since its founding, Biologics Consulting has become the go-to consulting partner for companies large and small seeking to bring innovative, safe, and effective products to market in the US. Our team of regulatory scientists, FDA consultants, and professional services staff has decades of industry and FDA experience that allows us to provide an unparalleled insider perspective for our clients. OUR DIFFERENCE The Biologics Consulting difference is all about the unique combination of regulatory expertise we have under one roof. Our team has depth of knowledge and breadth of experience across all product types and development pathways. This value proposition allows us to address the full scope of a client's regulatory and product development challenges from preapproval to commercialization. OUR EXPERIENCE AREAS - Biologics - Medical Devices - Pharmaceuticals - Biosimilars OUR SERVICES - CONSULTING – Regulatory, Product Development, Clinical Planning and Quality support. - SUPPORT SERVICES – Medical Writing, e-Publishing & Submissions, US Agent Services, Due Diligence OUR CLIENTS Our clients span the industry, from established multi-national pharmaceutical, biotechnology, and medical device companies to academic and research institutions. We also support small biotech and medical device start-ups. Since our founding, we have professionally services over 4,500 clients from 58 different countries.

BiologicsMD is developing novel therapeutics and therapeutic-device combinations for the treatment of hair-loss and bone disorders. The company's portfolio of hair cycle stimulators (HCS) are first-in-class treatments that hold the promise to restore hair and prevent hair loss in conditions of alopecia. The core technology relies on targeting physiologically active agents to Type l collagen found in skin and bone. BiologicsMD's targeted approach minimizes off-target effects and increases the time of exposure at the sites of function.

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.

We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Leveraging our extensive expertise in covalent binding chemistry and development, we built our proprietary FUSION™ System platform to advance a pipeline of novel covalent therapies. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of MENIN, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop covalent treatments against other high-value oncogenic drivers of cancer. Our goal is to utilize our capabilities and platform to become a leader in developing covalent small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.

OUR COMPANY BioMed Valley Discoveries, Inc., is a clinical stage biotechnology company with a mission to address unmet patient needs across a wide spectrum of diseases. Operating since 2007, BioMed Valley Discoveries advances its mission with commercial capabilities and resources typically unavailable to academic institutions. As a member of the Stowers Group of Companies, our stable long-term funding allows us to advance programs that may not fit within the model of more traditional clinical development groups. OUR APPROACH BioMed Valley Discoveries leverage several hundred experts at leading academic and clinical institutions to move projects forward in the early stages of clinical development. Our partners have a proven track record of scientific rigor and experience in efficient study execution. Our selection of development partners is based on our desire to address unmet patient needs and achieve critical development milestones as swiftly as possible. Through this approach, we endeavor to quickly answer scientific questions and determine next steps in the development process. OUR TEAM BioMed Valley Discoveries calls on the talents of a core leadership team of scientists who are focused, passionate, and committed to advancing new medical innovations to improve the lives of patients with difficult-to-treat diseases. Our team brings extensive experience from pharma, biotech, and academia. By utilizing unique advantages from each of these settings, BioMed Valley Discoveries creates a highly creative and functional drug development environment. We take a nimble and thoughtful approach to advancing programs with a focused sense of urgency, allowing for the most efficient path forward.

BiOneCure Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative ADC drugs for the treatment of cancers. The company was founded in 2017 by a group of industry veterans who have worked in global biopharmaceutical companies. Their research focuses on creating innovative technology platforms and adopting a multifaceted approach to develop new medicines that exceed current standards. The current pipeline covers classic ADCs, bispecific ADCs, and bifunctional ADCs, aiming to be the first-in-class or the best-in-class products.

Bionex’s mission is to realize the applications of bio-pharmaceutical and life sciences into commercial products and services that benefit human health. Strategically, Bionex engages in two areas of business activities. First, Bionex offers contract R&D services, from early-stage concept development, cGMP clinical supply manufacturing to full-scale commercialization, for bio-pharmaceutical products. Second, Bionex develops and out-licenses its own proprietary formulations, drug delivery technologies, and products related to medical, health food, and skin-care applications. Our expertise is focused on transdermal and transmucosal drug systems. We adopt a science-based, and yet pragmatic and out-of-box approach which often leads to fruitful outcomes, in time- and cost-effective manner. Bionex capabilities are its expertise in formulation science and analytical chemistry, full range of formulation/processing, analytical, and testing capabilities in cGMP facility, and well-connected network of industrial, academic and business consultants and advisors. Many of our in-house innovation R&D projects are funded by National Institute of Health (NIH), National Science Foundation (NSF), state grants and non-for-profit organizations.

Biopartners Inc. is a global biosample management company with operational offices in the United States and Eastern Europe. It is based in Los Angeles, California. Biopartners Inc. provides comprehensive solutions to support scientific projects.

Biopeptide Company offers design, synthesis, and production of quality peptides using t-Boc/Fmoc solid phase and solution phase technology.

Biophagy is a biopharmaceutical company, headquartered at The BioScience Center, Albuquerque, NM, USA. The company is focused on identifying drugs that modulate autophagy as part of a specific disease process in order to relieve patient symptoms. Biophagy is managing standard drug development programs in several therapeutic areas and is also developing an OTC/DTC kit that will focus on autophagy stimulation and measurement.

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company’s targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

We help scientists solve disease, develop drugs, and extend healthspan by building tools that simplify R&D, simulate biology, and untangle the complexity of life. Streamline computational analysis today. Discover drugs tomorrow.

BioTechnique is a contract manufacturing organization that provides standard and highly-customized cytotoxic and high potency sterile injectable liquid & lyophilized fill-finish services. Our state-of-the-art manufacturing facility is also equipped with a full-scale microbiology lab and offers regulatory affairs, laboratory, and project management support from investigational/clinical all the way through phase IV/commercial. Facility Capabilities: • Sterile injectable manufacturing & packaging for liquid & lyophilized products • Aseptic Vial Filling • Aseptic Lyophilization • Inspection • Formulation • Product Testing • Labeling/Packaging • Stability Storage • Process Design • Full service laboratory • Regulatory affairs support for product filings • Project management Product Capabilities: • Cytotoxics • Highly-Potent Compounds • Monoclonal Antibodies • Antibody Drug Conjugates (ADC) • Suspensions • Inactivated & Attenuated Live Vaccines Filling & Manufacturing Capabilities: • Grade A / ISO 5 Aseptic Filling Suite • 2mL to 100mL vials • 0.2mL to 100mL fill volume • Inline fill volume check weighing • Isolator • 13M2 Lyophilizer • Containment Unloading • Grade A / ISO 5 Capping • Post-Fill / Post-Lyo External Vial Rinse • Single-Use Disposable Manufacturing Train • Vial Inspection & Labeling • ICH Guideline Cold Storage • 2 to 8 ℃ • -20 to -70 ℃ • Stability Chambers & Warehouse Storage • Microbiology & Chemistry Labs

BioTherapeutics Inc (BTI) synergistically combines the power of advanced computational modeling, data analytics and artificial intelligence with translational experimentations to accelerate the development of innovative products for precision medicine and health. Our computational platform assembles biomedical and healthcare data from the molecular, cellular, tissue and population levels and leverages the latest innovations in technology to turn those data into answers to complex biological questions and solutions to healthcare's problems.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease, as well as Phase 2 clinical trial for the treatment of Parkinson’s disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology.

Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza.

Birch Biosciences uses Artificial Intelligence, bioinformatics, and high-throughput screening techniques to effectively engineer enzymes for recycling plastic.

Birchwood is a healthcare company that offers incontinence and wound care products to healthcare professionals and patients.

Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

Blacksmith Medicines is a biotechnology company focused on creating medicines targeting metalloenzymes. They have announced a merger with Forge Therapeutics to further their mission.

BlinkRx is the world's first pharma-to-patient cloud that offers a digital concierge service for patients who are prescribed branded medications. Patients benefit from transparent low prices, free home delivery, and world-class support on this first-of-its-kind centralized platform. With BlinkRx, never again will a patient show up at the pharmacy only to discover that they can't afford their medication, their doctor needs to fill out a form for them, or the pharmacy doesn't have the medication in stock. We are a highly collaborative team of builders and operators who invent new ways of working in an industry that historically has resisted innovation. Join us!

Bloom Science is a clinical-stage, central nervous system (CNS) company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs in Dravet syndrome; other rare epilepsies; Amyotrophic Lateral Sclerosis (ALS), a disease that causes nerve cells to die, which breaks the neural pathways, and causes extreme mobility loss over time; and neurodegenerative and cognitive disorders.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.

Blueprint Medicines Corporation, a precision therapy company, develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

BOC Sciences provides a wide variety of custom services which range from bulk compounds to specialty species in the pharmaceutical, agrochemical, and biotechnology industries. We are committed to providing our customers with the best products and services at the most competitive prices. Given diverse packing options for most of our chemicals, you are welcome to order the desired compounds in any quantities from a few mg to several kg along with all the relevant technical reports. We sincerely hope that our unremitting pursuits of excellence, success, and professionalism will add immense value to your research and development projects!

Bond Biosciences, Inc. is a privately held, clinical stage biopharmaceutical company focused on the discovery and development of first-in-class non-absorbed oral therapeutics that bind excess ions locally in the gastrointestinal (GI) tract to treat or prevent human disease.

Since its founding in 1987, BA Sciences has been a trusted provider of high-quality analytical testing services to life science companies worldwide. With a commitment to excellence, compliance, and innovation, the company has established itself as a premier analytical testing services provider in the industry. Originally located in North Reading, Massachusetts, BA Sciences moved its operations and headquarters to its current home located in Salem, New Hampshire. The footprint of the HQ laboratories facility started at 30,000 square feet but has since expanded to over 60,000 square feet, and there are additional laboratory and office facilities located in Framingham, MA and Morrisville, NC.

Bold and nimble, Boston Oncology is an innovative biogenerics company redefining excellence in the licensing and local development, manufacturing and distribution of US- quality medicines – across therapeutic areas. From our nerve center in Riyadh, we leverage the expertise, daring creativity, and unwavering determination of our international leadership team to provide customers with end-to-end, efficient, single-point-of-contact access to our diverse portfolio of world-class biogenerics. We do this because lives depend on it.

Transforming the right molecules into the best medicines™ Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.

Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive. Our Culture: At Boundless, you’ll experience what it means to be out in front of the wave. Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers. Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless. We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success. At Boundless, we’re all in. We are unbound by convention, bound to save lives. Career Inquiries careers@boundlessbio.com General Information Inquiries info@boundlessbio.com

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.

Sebela Pharmaceuticals is a U.S. pharmaceutical company with a market-leading position in Gastroenterology and a focus on innovation in Women's Health. Our Vision is to build the leading Gastroenterology company in the U.S., with a complementary focus on innovation in Women's Health, premised on our expertise in pharmaceutical development and commercialization. We value dedication, energy, and enthusiasm, and we focus on innovation and results while striving to achieve our corporate mission and vision. Sebela Pharmaceuticals is committed to cultivating an inclusive environment where all employees are treated with respect. We accomplish this by fostering a culture of diversity, equity and inclusion, which is essential to innovation and continuous improvement. Sebela operates from three locations with offices in Roswell, Georgia, Braintree, MA and headquarters in Dublin, Ireland.

Generic Pharmaceuticals

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together. BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company. BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; and UC San Francisco. The company was founded in 2015 and is headquartered in Palo Alto, California.

Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics'​ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory. For more information, visit www.bridgetherapeutics.com.

We are an investment banking and venture capital advisory firm that focuses on the healthcare industry. We have relationships with corporate partners, venture capitalists, hedge funds, family offices, and HNWI internationally. We represent companies and venture capitalists in biotech, pharma, diagnostics, devices, and imaging. BUSINESS DEVELOPMENT We listen to clients' goals for financing and do deep research for the right financial partner that includes family offices, angels, venture capitalists, hedge funds, and small funds. We provide personalized venture capital and investment banking advisory services. We keep the number of companies from one to three. We put together co-lead investors to help make the transition go smoothly. We represent multiple companies and venture capitalists in foreign countries looking for a foothold in California and the U.S. We work with U.S. companies looking for relationships internationally. We understand cultural differences and can help bridge the gap of communication on deals. FINANCE Expertise at targeting financial partners internationally. We create extensive relationships with private funding sources—from family offices to strategic angels. We build solid associations with healthcare and technology venture capitalists throughout the world. We comprehend the complexity of creating tranches in an investment. We work with lead investors and help put international syndicates together. We represent venture capitalists and individual companies and we understand the key points of closing deals STRATEGY We understand how to create materials that synthesize the company's strengths and message. We work with multiple CEOs and help design winning and concise pitches while providing personalized assistance on each call with investors and find areas that can be improved. We research influencers and non-profits in the scientific community that can help sway financiers' opinions. We analyze the current venture market for your company and find out which other companies in your space are getting financed and why. We design multi-tiered strategies of creating associations with the best financial partners.

We harness our team’s decades of experience in the biology of the serotonergic system to understand the effect specific receptors have on our body. From there, we create new and modify existing molecules in order to reduce unwanted side effects and accentuate positive therapeutic properties. This new generation of highly targeted serotonergic drugs will be able to reach specific patient populations that the compounds of today cannot.

BBI, headquartered in New York, is a privately held company founded in 2010 that specializes in acquiring and developing pharmaceutical and biotechnology products intended for the treatment and/or prevention of serious unmet medical needs. The COMPANY’s focus is to develop its products as quickly and as efficiently as possible, saving time and resources. We have partnered with leading academic institutions as well as a global network of drug development resources, eliminating the need and cost to build a "brick and mortar" biotech company. This innovative approach gives BBI big pharma capabilities without a big pharma infrastructure.

BrightSpec is an innovative life science tools company with a range of instruments that tap the power of molecular rotational resonance (MRR) spectroscopy. MRR enables the rapid, unambiguous molecular ID and quantitative analysis of mixtures, without separation, no chemometrics, and with no reference sample required. Not only can BrightSpec MRR complement other techniques such as Mass Spectrometry or NMR, in many cases MRR can solve problems not possible by these methods. For instance, MRR can easily distinguish between isomers (compounds with the same atoms but a different arrangement) or identify the exact site of deuteration of a molecule as well as quantify the number of each in the sample. BrightSpec is in the process of working with leading pharma, biotech, and academic players to develop breakthrough methods that will enable important advances in discovery. The company is also working with major chemical, oil & gas, consumer products, security, and environmental players to bring innovative solutions to these applied markets. The work is supported by research from a growing number of academic institutions as evidenced by a rising number of publications using BrightSpec instruments. BrightSpec builds on decades of federal and academic work in more than 110 research groups around the world. The technique was developed foremost in astrochemistry research. Using breakthrough technology developed by Brooks Pate at the University of Virginia, BrightSpec made this powerful technique of practical use by making the instrument significantly faster, cheaper, and easier to use. MRR spectra capture the unique set of rotational resonances, a fingerprint specific to a given molecular structure. These can be calculated theoretically based on quantum mechanics and are highly resolved. Isomers, isotopologues, diastereomers and enantiomers can be distinctly identified.

Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

BroadPharm is a leading customer-focused biotech company. We are dedicated to manufacturing and supplying high-purity PEG Linkers, Click Chemistry Tools, ADC Linkers, PROTAC Linkers, Drug Delivery Lipids, and Labeling Reagents to our clients worldwide. Founded in 2009, BroadPharm takes our customer needs as our highest priority. We have over 8,000 PEG Linkers, Click Chemistry tools, ADC Linkers, Lipids, Fluorescent Dyes, and Nucleosides. In addition to our broad catalog selection, we also offer IP-protected custom synthesis and bio-conjugation services for our clients in the pharmaceutical and biotech industries. We provide timely technical support to address our client's needs and offer technical advice for the best use of our new products. With our strong expertise in modern chemistry along with innovative and novel Lipid & PEG technology supported by state-of-the-art equipment, BroadPharm can help our customers accelerate their research through cost-effective and efficient solutions.

Bryllan is a contract manufacturing company that specializes in producing potent and cytotoxic compounds meeting US FDA and global regulatory standards.

BTS Research is a Contract Research Laboratory that delivers cGMP/GLP biological services to clients in the pharmaceutical, biopharmaceutical, biotech, academic research, medical devices and related industries.

BullFrog AI (NASDAQ: BFRG) is a technology-enabled life science company using advanced artificial intelligence (AI) to usher in the next generation of lifesaving therapies. With our leading-edge platform, bfLEAP™, we aid in accelerating and de-risking drug discovery and clinical development using one of the industry's most advanced graph analytic AI technologies. The Problem: The drug development landscape is littered with failed products and unrealized ROI — all while patients are desperately waiting for treatments that often don't come: • The cost of bringing a drug to market is $.8 to $2.8 billion • Almost 90% of drugs don't get there • The average time to market is 8.5 YEARS Our Solution: We're applying machine learning and AI in drug development to identify new potential therapeutic targets, optimize clinical trials, rescue and repurpose drugs for new indications, and discover new drug targets. By identifying hidden relationships in clinical data, we aim to mitigate risk and elevate the trajectory of precision medicine. Our Technology: The bfLEAP™ platform delivers in a way that neural network models cannot: Explainable AI. We use network models in an interactive graph machine learning format to display and explain your data insights with confidence. Say goodbye to "black box" processing and say hello to AI outputs you can explore and understand. Join Us in Our Mission: With our platform's superior capabilities, a high-powered team of industry experts, and a pipeline of exclusive in-licensed assets for clinical development, BullFrog AI is pushing the boundaries of AI-assisted drug development. Make BullFrog AI an extension of your organization and clear your analytical barriers. Leap into the next generation of drug development with BullFrog AI.

BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. Selectively targeting specific members and pathways within the TGF-β superfamily has the potential to be a meaningful class of therapeutics within oncology, inflammatory/immune, fibrotic, and metabolic diseases.

C2N Diagnostics is a molecular diagnostics company aiming to transform the early diagnosis and early treatment of Alzheimer's disease and related forms of dementia. They are developing and accelerating novel diagnostics and therapies for Alzheimer's disease, including the new PrecivityAD™ blood test for Alzheimer's disease.

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes.

Cadent Therapeutics is rapidly advancing apipelineof novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory.SK channels and NMDA receptors are ion channels that are critical formodulating the strength, timing, and integration ofcommunication betweenand within neurons and neuronal networksin the central nervous system.

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an oral therapeutic designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular (CV) conditions. Cadrenal strives to improve outcomes and reduce adverse events for these patients such as strokes, heart attacks, bleeds, and deaths. These patients also lack approved chronic anticoagulation options besides warfarin, well-known for its serious side effects and frequent drug-drug interactions, resulting in complicated treatment management. Cadrenal’s drug candidate, tecarfarin, is a new VKA anticoagulant with extensive clinical data showing it is potentially superior and safer than warfarin, resulting in fewer adverse events. Tecarfarin is metabolized via a different pathway than warfarin and data demonstrate that its efficacy is unaffected by common drug-drug interactions or kidney impairment, which are common in these patients. Phase 2/3 clinical trials show that tecarfarin may offer more stability and time in therapeutic range (TTR) that inversely correlates with major events. Tecarfarin received an orphan drug designation for advanced heart failure patients with left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (ESKD) patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal clinical trials with LVAD patients along with clinical and commercial partnership opportunities to advance tecarfarin. The company’s plans also include studying patients with mechanical heart valves who experience anticoagulation difficulties because of genetic warfarin resistance, polypharmacy, or kidney impairment. For more information, please visit: www.cadrenal.com.

Caeregen Therapeutics discovers and develops novel therapies which repair, restore, and protect damaged and diseased tissues by reactivating the pathways and signaling which accompany normal cellular and tissue development. Our revolutionary regenerative medicine approaches have the potential to restore lost or degraded functioning to diseased tissue and organs.

CalChem Synthesis is a Contract Research Organization (CRO) serving as an outsourcing partner for the biotech and pharmaceutical companies and research institutions. The company mission is to provide high quality non-GMP chemistry services to the chemical community and to maintain customer satisfaction. Our services are based on the belief that our customers' needs are of the utmost importance and we are committed to meeting those needs. The experience of CalChem's team in synthetic organic chemistry and process research and development ensures that all projects are delivered with highest quality standards and on time. CalChem is located in the heart of "Pharma Corridor" in Torrey Pines, San Diego. Our leadership team has over 45 years of combined experience in different sectors of drug discovery and development in pharma industry. If you are located in Southern California, benefit from our services in your backyard and discuss progress of your projects in face-to-face meetings with our chemists on a weekly basis. For national and international clients, progress reports can easily be discussed by conference or video calls. We would welcome the opportunity to earn your trust and deliver you the best services in the industry. With our experience in pharmaceutical contract research and development, we ensure that your projects will be handled smoothly and in your best interest.

CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr. Stauderman’s work includes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted by CalciMedica’s drugs. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology.

CenExel is a leading integrated, wholly owned, nationwide clinical research site network comprised of 18 Centers of Excellence in major metropolitan areas across the U. S. With 40+ years of experience, our Centers of Excellence deliver deep scientific expertise, premium data, operational efficiencies, and exceptional patient engagement to drive successful complex clinical trial outcomes. The world's most results-driven Pharma, Biotech, and Clinical Research Organizations trust our strategic approach and benefit from our collaboration and unified sites' commitment to real world solutions. Rely on us to confidently progress from site selection to study close-out and accelerate life-changing therapies. Get more value from your clinical trials with CenExel.

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Calosyn has developed intra-articular therapeutic drugs for osteoarthritis of the knee based on proprietary combinations of ion channel modulators (ICM’s) currently in clinical use.

Calviri’s mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine. For more information, please visit www.calviri.com.

CAMAG is the world leader in High-Performance Thin-Layer Chromatography. We provide high-end instruments, tools and concepts for TLC/HPTLC. Additionally, we support our clients with training, technical and contract laboratory services. Wherever complex substance mixtures are analyzed (e.g. herbal, environmental or forensic samples), TLC/HPTLC often is an excellent alternative to GC and HPLC. Moreover, it has proven value as a solid quantitative analysis technique in quality assurance of food, pharmaceuticals and other industrial products. Since 1961, CAMAG is dedicated to the development and manufacturing of instruments, software and consumables for all steps of the TLC/HPTLC procedure. Our products are truly Swiss made and have an excellent reputation throughout the world.

Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services. With over 40 years of experience and a growing team of over 2,000 experts servicing global clients from North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and finished dosage form development and manufacturing.

Cambrian Bio is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.

CancerTargetedTechnology develops innovative agents for cancer that accurately detect early and advanced disease, monitor treatment efficacy

At Candel Therapeutics, we are developing immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications. Candel’s products are designed to improve survival while maintaining quality of life – from early- to late-stage disease.

Canget BioTekpharma is a biotech and biopharma company used to develop novel, cancer-targeting anticancer agents.

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Our strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.

Cantex Pharmaceuticals, Inc. is a pharmaceutical company developing treatments of cancer, complications of COVID-19 infection, and pulmonary inflammatory diseases.

Cao Pharmaceuticals is an early clinical stage oncology drug development company with a rich and deep history. We are committed to develop highly effective drugs with low and manageable toxicity for various cancers. And within much shorter timeframes compared to traditional chemotherapy development. Cao Pharmaceuticals is currently conducting a Phase I trial with their lead drug. Phase II trials are scheduled for Q3 2017.

Capra Biosciences is developing a new technology that will make the manufacturing of chemicals using biology cost-competitive with petroleum-based products. Significant advances in synthetic biology have been made over the past 20 years, enabling a multitude of products with lower environmental impact and potentially better performance than their petrochemical counterparts. However, cost-competitive large-scale manufacturing of these products remains a significant bottleneck to their adaptation. Our technology tackles this bottleneck through an innovative bioreactor design that promises to significantly reduce end-to-end manufacturing costs.

We are a group of Pharmaceutical Industry Executives, Military Vets, and Civic Volunteers dedicated to averting Public Health crisis related to Lead Poising, Radiation Poisoning, and other toxic heavy metals found in and around the environment in both the U.S. and developing nations. Captura is developing a drug called C2E2 for treatment of individuals who have been contaminated by highly radioactive compounds, either by accident or following a nuclear terrorism event. C2E2 is a ‘radionuclide decorporation agent’ that works by binding radioactive elements in the bloodstream and enhancing their elimination before they can be trapped inside the liver and bones where they can do maximum damage.

Analytical, Microbiological, Pharmaceutical, OTC, Contract Lab, Consulting for Analytical, FDA Deficiency, Water Testing , High Resolution GC-TOF-MS

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).

Cardax is developing proprietary astaxanthin therapies for large unmet medical needs where oxidative stress and inflammation play important causative roles. Introduction Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, as conferred by U.S. Food and Drug Administration (“FDA”) Generally Recognized as Safe (“GRAS”) designation at certain doses. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding.

Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and Cardiff's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardurion Pharmaceuticals is a next generation cardiovascular company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by an experienced team of CV experts and industry veterans, we are developing groundbreaking clinical programs in PDE9 and CaMKII inhibition. We take a strategic portfolio approach driven by in-house drug discovery and our office of strategy and have concluded foundational partnerships with key strategics and investors, including an up to $300 million dollar investment from Bain Capital to support current programs and pipeline growth. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

Drug discovery and development to target the root causes that drive cancer and metabolic diseases using Chemotype Evolution.

Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra's high throughput LSA, LSA-XT, and Ultra platforms for monoclonal antibody (mAb) and small molecule screening and characterization combine patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading analysis and visualization software. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms. The LSA-XT and Ultra instruments introduce enhancements to Carterra’s flagship product, the LSA, increasing sensitivity and enabling new applications in biotherapeutic discovery and small molecule analysis. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. For additional information, please visit www.carterra-bio.com.

CartilaGen Inc. is developing an intra-articular injection of a small-molecule drug capable of preventing post-traumatic osteoarthritis. CartilaGen's solution aims to provide an unprecedented disease-modifying treatment to an area of medicine that remains an unmet medical need.

Cary Pharmaceuticals is a pharmaceutical development company. The Company is advancing the development of QuitPak®, a patented treatment for smoking cessation, and a novel catheter lock solution to prevent clot formation in catheters. The Company is led by an experienced management team and Board of Directors, including Douglas Cary (President) a former Abbott Laboratories executing; Carl Schwan (CFO) a former CFO for two successful initial public offerings that raised $80 million; and Lester Crawford (Director), Former Commissioner of the U.S. Food and Drug Admininstration (FDA).

Cascade Biocatalysts is creates more productive enzymes for economical biomanufacturing of sustainable chemicals. Cascade addresses the growing need for stable, long-lasting biocatalysts using their patent-pending enzyme immobilization platform.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited; Juventas Cell Therapy Ltd.; Pharmathen Global BV; and Cleave Therapeutics, Inc. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company, is using two lentiviral platforms to develop and commercialize therapies for genetic diseases.

At Castor, we believe in the power of clinical research and the power of technology. And we know that together, these forces can help extend human healthspan. To achieve this reality, we must make patient-centered clinical trials a possibility for everyone, anywhere in the world. That's why we are using technology to capture the world's research data and optimize each activity of a clinical trial. From recruitment to monitoring, our modular clinical trial platform makes it easier to design and deploy trials, enroll and engage patients, collect data and analyze results. Each module can be used individually or in unison with others, providing the ability to customize each solution to fit your needs, and grow at your own pace. That's delightful for patients, effortless for study teams, risk-free for sponsors.

Catalyst is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases.

Catherych Incorporated is an ingredient supplier to the natural products and nutraceuticals industry.

CD BioGlyco provides various carbohydrates, glycoconjugates, enzymes and related products, as well as many glycobiology related research services.

CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems.

Celcuity is a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them.

CeleCor Therapeutics - We’re a biotechnology company on a mission to develop therapies that will get patients with a heart attack to the hospital with open coronary arteries. We focus on developing pre-hospital therapies, because early action is crucial to preserve heart muscle. The longer a coronary artery is closed, the more severe the damage to the heart. Starting treatment before patients reach the hospital, significantly improves the chances of a positive outcome. We’re developing zalunfiban; a prompt, potent, and predictable medication designed for treating patients with a heart attack before they reach the hospital. Zalunfiban has the potential to fulfil a significant unmet medical need in the pre-hospital phase of heart attack care. We’re currently running the CeleBrate trial: a pivotal Phase 3 prospective, blinded, randomized, placebo-controlled, international, multicenter, study designed to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in patients with ST-segment elevation myocardial infarction in the pre-hospital setting.

Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious diseases, rare diseases and cancers.

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Please visit Cellceutix's web site at www.cellceutix.com.

Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody-drug conjugates, immune system modulators and other protein-based therapeutics that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, Instagram, YouTube, and Facebook.

Cellibre is a best-in-class manufacturing technology company.. Employing an organism-agnostic approach, we turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Our world-class scientific team has led programs from napkin to commercial, pioneering revolutionary breakthroughs in energy, ingredients, medicines and more. Member: BioMade, Defense Industrial Base Consortium (DIBC)

Celloram Inc. is a preclinical stage company founded in 2018. Our team of experienced leaders and scientists share a passion for improving the health and well-being of patients and families affected by cancer and chronic disease. Celloram has a deep sense of social responsibility. We are dedicated to the community in which we reside and work, and where we honor our commitment to promote diversity by inspiring, educating and developing the next generation of scientists and leaders. Celloram now leverages its key discoveries to develop unique forms of cell therapy and small molecule therapeutics that harness our body’s own unique potential to heal and battle chronic illnesses including cancer, autoimmune disease, chronic inflammatory and metabolic disorders. Our mission and vision stem from our strong belief in the potential of new, less toxic therapies with the power to ignite our body’s self-healing process. With an ideal location at University Circle, Cleveland, OH, Celloram has benefited greatly from partnerships with health care leaders at two of the nation’s leading academic medical centers, including Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center. Supported by a highly motivated and dedicated group of partners and investors, Celloram has developed a pipeline of four unique therapeutics: Sopprimerex, Protexi, NOVS-100, and CLM-022. These cutting-edge therapies are in distinct phases of preclinical development and are rapidly advancing through essential steps that will position each core asset for entry into clinical trials and evaluation by the FDA. Our team at Celloram is committed to sharing our discoveries and advancing them for the benefit of human health.

Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” AMHR2 program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information visit www.celmatix.com.

As an AAHRPP-accredited IRB, Salus IRB is committed to upholding the highest standards in human research protection while providing concierge customer service and consultative expertise. Salus works with sponsors and investigators to add value by delivering IRB services in a convenient, reliable, and efficient manner. Salus IRB provides ethical review for all phases of research in a variety of therapeutic areas and study designs in the pharmaceutical, biotech and medical device industries, and for single- and multi-site trials. We also provide ethical review for behavioral and social sciences research including data collection, repository, surveys, outcomes, and registries. With multiple meetings weekly and industry-leading 21 CFR Part 11 compliant technologies, our turnaround time for review is 24-48 hours. Our online submission platform, SafeSync and virtual workspace, Globesync™, allow secure, 24/7 access to your complete IRB study file throughout the process.

Cenna Biosciences is revolutionizing Alzheimer's treatment with proprietary small peptides and molecules that inhibit beta amyloid production. The company is focused on developing disease-modifying drugs for Alzheimer's disease using a proprietary novel mechanism.

Cerevance is a revolutionary pharmaceutical company using the proprietary NETSseq platform to develop novel symptomatic and therapeutic treatments for central nervous system (CNS) disorders.

Cerevel Therapeutics is working relentlessly to find paths through complexity in an effort to bring real progress and new treatment options to people living with a broad range of neuroscience diseases. On August 1, 2024, AbbVie has acquired all outstanding Cerevel common stock for $45.00 per share. It is expected that Cerevel's common stock will cease to trade on the NASDAQ stock exchange prior to market open on August 1, 2024. This acquisition is expected to be accretive to adjusted diluted earnings per share (EPS) beginning in 2030.

Cerium Pharmaceuticals is dedicated to creating efficacious therapies for patients with kidney diseases. Cerium is currently focused on developing the first drug approved for a very rare kidney disease called Primary Membranous Nephropathy (PMN). There are approximately 75,000 PMN patients in the US and approximately 3,000 newly diagnosed PMN patients per year.

CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry. In August, 2023 EIP Pharma merged with Diffusion Pharmaceuticals, retaining EIP’s development pipeline, but changing their name to CervoMed (CRVO). For more information about the company and updates, please visit www.cervomed.com/ or follow us on Twitter at @Cervo_Med.

Ceutical Laboratories provides services to the pharmaceutical, medical device, dietary supplement, veterinary, cosmetic, and food industries. Ceutical Labs provides formulation development, design development, project management, process development, analytical testing (chemistry, microbiology, and physical testing), consulting, training, regulatory submissions (IND, NDA , ANDA, 510K, PMA, etc.), regulatory compliance, ESG submissions, quality system implementation, validation support, FDA management, auditing, IT solutions, and marketing expertise. YOUR SUCCESS is our goal. Analytical testing equipment includes GC, GC/MS, HPLC, HPLC/MS, HPLC/MS/MS, ICP, AAS, XRF, Polarimeter, and much more. Our formation expertise includes Rx, solid dose, topicals, and parenterals. Our laboratory has over 50,000 square feet. Our training facility has over 10,000 square feet. We will meet and exceed your expectations. We seek to help our customers achieve regulatory compliance. Our customers who have fully implemented our quality systems have received very few to no observations. We are routinely inspected by US FDA and Health Canada. Our goal is to remain compliant. We are a third party sampling and testing laboratory for US FDA.

cGMP Validation was established in 1997 as a full service validation/compliance firm offering services for the pharmaceutical, bulk pharmaceutical, animal health, biotechnology, biologics, medical device and medical diagnostic industries. Our team is comprised of a group of professionals with considerable experience within the pharmaceutical industry. Educational disciplines consist of chemistry, microbiology, engineering, pharmacy and computer science. Team expertise was not only developed through working with operating companies giving them a unique ability to coordinate with client personnel to assure that all facets of the project start-up and validation are considered. Many of our project leaders have been middle to senior level Quality Assurance Managers, Production Managers or Facility Managers thus having an excellent understanding of industry standards and FDA expectations. Successful projects have been performed throughout North America as well as Internationally. Clients range in size from small to large for pharmaceutical (finished and bulk), biological, medical device and diagnostic manufacturers. cGMP prides itself on all projects regardless of size, being given the same professional attention and management.

CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for global development in California, and it is publicly traded on the KOSDAQ exchange (083790). CrystalGenomics has a product on the market and is developing several novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation NSAID for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG-745, an epigenetic agent applicable to various types of solid and liquid tumors and currently, phase 2 clinical trials are ongoing for pancreatic cancer and MDS. The second clinical stage program is CG-549, a novel class antibiotic for MRSA where its phase 2a skin infection study in the US had been completed with a positive outcome of 100% clinical cure rate. The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which utilizes the integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies. By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions for improving human health. For more information, please visit: www.cgxinc.com or www.crystalgenomics.com.

Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive, therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company’s portfolio also includes pre-clinical work on other sodium channel receptor subtypes and the Company intends to explore these and other compounds for the treatment of additional pain indications.

Character Biosciences (formerly Clover Therapeutics) is a precision medicine platform that is unlocking the patterns of age-related diseases in people of diverse backgrounds. Our mission is to use human genetics to understand what drives diseases so we can discover targeted therapies to more effectively treat patients - many of whom lack any treatment options today. Character partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.

Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on the development of better treatments for brain disease.

Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, in a Phase 1/2 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (“NSCLC”). In addition, Checkpoint is currently evaluating its lead antibody product candidate, CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in a Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers. Checkpoint plans to develop CK-301 as a treatment for patients with NSCLC and other solid tumors. Checkpoint is a majority-controlled subsidiary of Fortress Biotech, Inc., and is headquartered in New York City.

ChemBridge Corporation is a global provider of enabling chemistry products and contract research services for small molecule drug discovery and chemical biology research. ChemBridge's extensive portfolio includes over 1.3 million diverse and target-focused screening compounds, 14,000 chemical building blocks, 10,000 synthetic macrocycles, our Hit2Lead.com on-line chemical store, and high-end, research-intensive custom library and synthetic/medicinal chemistry services. ChemBridge's research products and services are supported by an experienced, dedicated and friendly customer service and project management team at our San Diego headquarters and by ChemBridge's 25-year track record of innovation, quality and deliverability.

CheminPharma is a biotechnology services company based in Woodbridge, CT. Founded in 2007, the main objective is to provide high-quality medicinal chemistry focused drug discovery services to biotechnology and pharmaceutical sector. In recent years, CheminPharma has expanded into other closely related businesses. CheminPharma's business rests on the following two pillar strategies: 1. Drug discovery research services 2. Novel Research tools & reagents We are looking to form partnerships with small molecule biotechnology and pharmaceutical companies where we can provide essential chemistry services to aid in the drug discovery process. If you are interested in a collaboration opportunity, feel free to contact us directly!

Chemi Nutra offers science-based nutritional ingredients that address a variety of nutrition and performance-related applications. Chemi S.p.A., the parent company of Chemi Nutra, is a 40+ year-old, privately held nutraceutical and pharmaceutical company, based in Milan, Italy, with several production facilities located in both Italy and Brazil. The combined expertise allows our companies to be engaged in the entire process of bringing a nutraceutical to market — innovation, development, manufacture, marketing, and sales. We offer valuable assistance in developing unique and profitable nutritional products utilizing our knowledge of science, creativity, and targeted marketing.

LEADING THE SUPPLY OF HIGH QUALITY GENERIC APIs 21st Century economic, social, technical and regulatory dynamics are dramatically changing the pharmaceutical world making it more challenging than ever to find profitable opportunities. That's why it's important to work with a supply-partner who knows how to navigate through the tough issues, help you overcome obstacles and get you to the market fast to gain competitive advantage. Established in 1982, ChemWerth is a full service generic drug development and supply company providing high quality API's to regulated markets worldwide. Through exclusive development and partnerships with API manufacturers, ChemWerth provides expertise in product selection, development, analytical and regulatory services, and strong project management to ensure the highest standards of quality. We are committed to providing our customers with a distinct competitive advantage. Our team of technical, analytical, regulatory and marketing experts can enhance your business by: 1. Advancing your product development; 2. Ensuring the manufacturing facilities we represent maintain a high level of compliance with ever-evolving cGMPs; 3. Collaborating with manufacturers in establishing appropriate protocols and methodologies to prepare a sound and complete DMF; 4. Sourcing APIs from China, India, Germany and the US to provide our customers with the best value; and 5. Advancing Paragraph IV filings through our exclusive API development and supply partnerships.

Since 2005, the Chicago Research Center's dedicated team of qualified, board certified physicians, licensed clinicians, psychometricians and trained support staff have taken part in more than 750 clinical trials over the past 12 years. As an independent research center, CRC specializes in the pharmaceutical and biotechnology industries, focusing their studies in areas including psychiatric, sleep, and general medicine. Located in Portage Park, but serving all of Chicagoland, CRC takes the utmost care to ensure participants of their clinical trials have a safe and rewarding experience. The results of their efforts continue to exceed sponsor expectations for reliability, dependability, human protection, and overall performance. With a combined 25 years of expertise in the industry, Chicago Research Center continues to impact lives through novel developments and provides leadership and continuity to the research industry.

At Chimerix, we are on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. With a focus in oncology, we are devoted to filling gaps in the treatment paradigm.

ChromaCode is deploying a solution for mid-density, multiplexed analysis, high-definition PCR or HDPCR​.COVID-19: EUA (06/2020) for its HDPCR SARS-CoV-2 Real-Time PCR

Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform.

Cime has harnessed recent advancements in synthetic chemistry to develop a proprietary platform unique to the industry that is faster, more efficient, and more cost effective than current solutions By combining the synthesis and screening stages of drug discovery, we significantly accelerate the Design-Make-Test-Analyze paradigm.

Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.

CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal, and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients’ quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio.

CiRC is a privately held, cell therapy company, developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Founded in 2019, CiRC is in pre-clinical development for the use of chemically induced retinal cells for vision restoration and specifically pursuing a treatment for Geographic Atrophy Age-Related Macular Degeneration (“Dry AMD”) and advanced Retinitis Pigmentosa (RP).

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. They recently raised Series B and Series C financing from The Column Group and NextTech Invest. Circle Pharma design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. They do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). They have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners. Circle Pharma workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. They deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.

CisThera Inc. is a privately owned biopharmaceutical company in the Seattle area. CisThera’s mission is to develop innovative therapeutics to treat cancer, autoimmune diseases, as well as chronic kidney and liver diseases. CisThera is taking a novel approach to identify drugs with greater efficacy that broadly inhibit validated contributors to disease pathogenesis.

Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

Claris Bio works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision-making. The company is focused on developing topical formulation technology designed to treat orphan ophthalmic disorders, such as neurotrophic keratitis, and cure corneal diseases.

Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

bio-analytical services

Clinical Investigation Specialists, Inc. (CIS), is an independent, premier Clinical Research Management Organization. CIS has conducted Phases I-IV clinical trials for pharmaceutical and biotechnology companies. CIS is committed to providing personalized attention and services by utilizing resources other companies cannot provide. We maintain a proactive pursuit of value added services to meet our clients' changing needs. Our extensive CIS/MD Network consists of the most qualified Board Certified physicians covering all major therapeutic areas. We are proud to break the mold by distinguishing ourselves as a clinical research management organization that is on the cutting edge of medicine. CIS offers not only services you may receive from a CRO & SMO, but also services encompassed by a hands on Research Management Organization. Sounds like a smart choice for companies looking for an efficient means to move their products through the pipeline with more personalized attention. There are many advantages when you choose CIS for your upcoming trials. Our experienced Investigators and Research Coordinators offer innovative ideas every step of the way to help you achieve your desired results.

Clinical Trial Network offers quality medical attention to the Houston area, while gathering data to generate industry-leading clinical research to pharmaceutical, bio-technology sponsors, and leading Contract Research Organizations.

Cloud Pharmaceuticals is a pharmaceutical company that specializes in in silico therapeutics, revolutionizing drug discovery and development processes.

CMTx Biotech is commercializing a pipeline of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations for the host-modulatory treatment of diseases with high unmet needs. The company’s lead drug candidate is a clinical-stage, orally-administered small molecule (incyclinide / CMT-3 / COL-3) for the treatment of hospitalized sepsis patients at risk of septic shock, multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS), including from SARS-CoV-2 infection (COVID-19) and other infectious diseases. Our clinical-stage drug candidate has already demonstrated impressive efficacy in a number of animal models of sepsis/ARDS/MODS across multiple species (rats, mice, pigs, sheep). It has also been evaluated in over 450 patients across eleven Phase I/II clinical studies, which showed that the drug is well-tolerated. CMTx Biotech also has a pipeline of pre-clinical stage analogues for the treatment of diseases with high unmet need.

CNBX Pharmaceuticals is a publicly traded company (CNBX: OTCQB) and developer of the world's first cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer based on the company's novel and proprietary formulation CNBX™️ RCC-33.

Since 1996, CNS Healthcare has safely and effectively managed thousands of clinical trials in Orlando, FL; Jacksonville, FL; and Memphis, TN. Our work has resulted in the collection of information about pharmacological developments that have given way to some of the most widely prescribed medicines today. Our work continues on today, with more staff and larger facilities, in order to exceed the expectations of our patients and industry partners.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

COARE Biotechnology is a multidisciplinary drug development company that seeks to advance the current treatment modality of patients with aggressive cancers by coordinately targeting aspects of both the primary tumor and the biological processes that effect metastatic initiation and progression. Our team has garnered worldwide acclaim for their groundbreaking scientific discoveries in support of the novel therapeutic platforms developed here at COARE Biotechnology. We have identified key components within cancer biology that have not been targeted – until now.

Cocoon Biotech is a biotechnology company that specializes in developing a drug-delivery platform using fibroin protein derived from silkworm cocoons.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising preclinical and early clinical stage antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Cognigenics develops innovative RNA-based gene therapies targeting memory loss, cognitive decline, anxiety associated with mild cognitive impairment and other neurocognitive and neuropsychiatric disorders. Our intranasal delivery platform targets neuronal receptors in the brain involved in CNS disorders including anxiety, and Mild Cognitive Impairment.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer’s disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson’s disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Colby Pharmaceutical Company is developing drugs for inflammatory conditions.

Collaborations Pharmaceuticals, Inc. works on drug discovery for rare and neglected diseases. We develop and license our AI software as well as provide fee for services for pharmaceutical and consumer product services. To date we have won with collaborators $23.5M in grants since 2016.

Collaborative Drug Discovery's CDD VAULT is a hosted biological and chemical database that securely manages your private and external data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy-to-use web interface. The available modules within CDD Vault include Activity, Registration, Visualization, Assays, AI, Automation, Curves, Inventory, and Electronic Lab Notebook (ELN). Each module is designed to optimize various aspects of research and data management, enhancing the overall efficiency and productivity of scientific workflows. CDD Vault is a system your entire team can actually use! Engineered for Ease of Use CDD Vault allows you to enjoy the benefits of large enterprise systems without the administrative burden or expense. Modern Cloud Solution Saves Money CDD Vault is affordable to academic laboratories, research foundations, and small companies. Beats Juggling Spreadsheets of Screening Data! Eliminates the Risk of Data Loss CDD Vault provides a secure environment to collect all your compound and screening data. Get Better Results from Unified Data CDD Vault consolidates all your compound and screening data in one place. This makes analysis easier, more consistent, yielding results more quickly. Securely Store Experimental Data in a Private Hosted Vault Data Migration is a Snap CDD Vault can provide easier access and better management of your existing data too. Safely Share Data CDD Vault allows you to selectively share data in real time with your designated researchers in your own lab or across the globe. Security is Built-In - CDD Vault is protected with SSAE 16 Type II certified cloud storage on locked and guarded hardware. https://www.collaborativedrug.com/pages/benefits CDD VAULT from Collaborative Drug Discovery https://www.collaborativedrug.com

Collaborative Medicinal Development LLC is a company based out of 184 Bulkley Avenue, Sausalito, California, United States.

Collegium Pharmaceutical is a specialty pharmaceutical company committed to being the leader in responsible pain management. For nearly two decades, Collegium has been focused on developing and commercializing new medicines for pain management that reflect our Core Values and our commitment to people suffering from pain, providers and our communities. The result of those efforts is a portfolio of meaningfully differentiated medications to treat moderate to severe pain.

Community Clinical Health is a community of mental health professionals dedicated to the compassionate and ethical conduct of clinical trials of investigational pharmaceuticals for person with mental illness.

Conagen is an accomplished biotechnology company located in the greater Boston biotech corridor. We innovate and develop synthetic biology solutions for supporting global partners across a spectrum of current and developing markets. From our proprietary strain development to fermentation and process scale-up, Conagen impacts partners’ abilities to sell and market products in the food, nutrition, flavor and fragrance, pharmaceutical, and renewable materials industries. Our bio-manufacturing capabilities, coupled with extensive platforms of enzymes and microorganisms, gives us the edge in commercial biotechnology. Nature is our inspiration for designing metabolic pathways, improving production organisms, and optimizing production processes. Our discovery and development methods foster sustainability and improve efficiency—from lab to world scale. Plant biology ignited the spark for the creation of Conagen. Today, our bioengineering teams are experts in enzymatic bioconversion and fermentation technology. Nature is our guide for innovating ways to produce natural products and materials. This approach gets us to market faster with better products made competitively and sustainably. Simply, our distinction is creating molecules that are identical to what nature produces. Many of the innovative natural products we make at Conagen are truly proprietary. They are the only ones on the market that are made by natural fermentation which means they are produced biologically and sustainably unlike most chemically synthesized products. As a vertically integrated biotech company, we engage in research and development as well as world-scale production. The advantage at Conagen is our ability to direct the manufacturing of our products. We can rapidly scale our strains to produce what our partners need while maintaining the highest level of quality control throughout the entire process. Scaling up from micrograms to metric tons is our expertise.

Concentrx Pharmaceuticals, Inc. Management Team; Gilbert S. Mott, Jr.; Eric C. Richardson; W. James Alexander

ConfometRx is a leader in G protein coupled receptor (GPCR) structural characterization and analysis and GPCR-targeted drug discovery.

We are pioneering a new class of drugs that activate the immune system to recognize cancer cells as foreign invaders.

Tianjin Conjustar Biotechnology Co., Ltd. is a researcher and developer of peptide-drug conjugate intended for oncology treatments. The company was established in early 2022 and is located in Tianjin Airport Free Trade Zone. It was founded by Fosun Health Capital and focuses on cooperative development and independent research.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company’s lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Consegna Pharma Inc. is a specialty pharmaceutical company with a mission to create best-in-class long-acting medications.

ConSynance is a clinical-stage virtual biopharmaceutical company focusing on rare diseases in the central nervous system. Our lead asset is CSTI-500, a small molecule first-in-class triple monoamine reuptake inhibitor (TRI) with the potential to benefit patients with Prader-Willi syndrome (PWS) and other related disorders. CSTI-500 was generally safe and well-tolerated in Phase I clinical trials in healthy humans and demonstrated CNS target engagement via PET that predicts efficacy in patients. ConSynance is currently recruiting for a Phase I study in PWS patients (clinicaltrials.gov: NCT05504395) to study the pharmacokinetics and safety in this patient population. We also have a preclinical candidate, CSTI-200, a small molecule, first-in-class GlyT-1 Inhibitor for the treatment of L-Dopa-induced dyskinesia (LID) in Parkinson’s disease (PD). Based on recent preclinical evidence, GlyT1 inhibition may have a niche in PD not only for the treatment of dyskinesia, but motor fluctuations and PD psychosis. CSTI-200 has a competitive mechanism of binding that provides a “self-regulating” property for potentially better tolerability compared with non-competitive GlyT-1 inhibitors. In 2021, we reached an asset purchase agreement with Harmony Biosciences for our second drug, (formerly CSTI-100, now renamed HBS-102.) This potential first-in-class MCHR1 antagonist has the potential to treat a variety of neurological disorders. ConSynance currently holds the license of this drug for the Greater China region and Harmony has global commercialization rights outside of Greater China.

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.

Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Contineum targets biological pathways associated with specific clinical disabilities, that once modulated, can demonstrably impact the course of disease.

Continuity Biosciences, LLC, is dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and ultra-long acting drug delivery. The company seeks to leverage the immense potential at the intersection of biopharmaceuticals and medical technologies, especially in creating combination products that can help realize the full potential of remarkable therapies. While our foundation is built on technologies licensed from Prof. Grattoni's pioneering research at the Houston Methodist Hospital, we plan to continuously expand our technology portfolio to provide our partners with diverse options for their product presentation strategies.

CONTRACT PHARMA is the multi media information outlet dedicated to bio/pharma outsourcing. From drug development to manufacturing, we cover the latest developments, views and opinions from industry leaders in print and online. CONTRACT PHARMA offers advertising opportunities in our print magazine, Contract Pharma Direct weekly e newsletter and on contractpharma.com. We are the only worldwide print publication focused on Bio/Pharma contract services, delivering a total qualified circulation of 20,013. (VAC audit statement) On Sept. 26-27, 2024 CONTRACT PHARMA will host its 23rd Annual Contracting & Outsourcing Conference & Tabletop Exhibition. This event brings together speakers from the FDA, industry leaders, and expert analysts to discuss issues critical to success for Pharma & Biopharma outsourcing. The one-day Tabletop Exhibition of 160 top contract service providers provides great exposure to outsourcing decision makers. CONTRACT PHARMA's Corporate Capabilities and Contract Services Directory is the largest single source for company profiles and contract services. This standalone print issue showcases the services of Bio/Pharma contract service providers. The Contract Services Directory is also available online at www.contractpharma.com/csd. It's an indispensable guide for contract services in print and online. Every week, thousands of Bio/Pharma outsourcing professionals go to www.contractpharma.com to read current features, find archive stories, and get breaking news and online exclusives. We also e-mail CONTRACT PHARMA DIRECT, our weekly e-newsletter, to more than 20,000 people. CPDirect is filled with the latest news, our most recent articles, and links to our popular annual features and upcoming meetings. Free subscriptions are available on our website. Contact us for more information on how your company can get involved with Contract Pharma.

Coquí RadioPharmaceuticals is a radiopharmaceuticals company focused on creating a scalable and reliable domestic supply of Mo-99 to provide low-cost diagnostics and treatments to patients.

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others.

We’ve been unlocking the potential of cortisol modulation for more than 25 years. We’re leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.

CoRegen is leveraging its groundbreaking master gene regulator platform to develop a broad range of therapeutics capable of controlling numerous genes throughout the body, with lead indications in solid tumors.

CoreRx, Inc. is an industry leading Contract Development and Manufacturing Organization (CDMO), providing innovative drug formulation development, GMP manufacturing and packaging solutions to global pharmaceutical and bio-pharmaceutical partners. With its state-of-the-art, multi-site campus in Clearwater, Florida, CoreRx delivers value-added solutions to its partners, from clinic to commercial scale and across a range of dosage forms.

Corgenix is part of the SEBIA Group. Located outside of Denver, Colorado, USA, Corgenix is a CAP/CLIA accredited laboratory specializing in clinical studies, clinical trial management and physician-ordered patient testing. Corgenix is also a experienced in CDMO—Contract Development and Manufacturing Organization. Corgenix is a highly capable strategic partner with history of success; our main client groups are Biotech companies, Pharmaceutical industry, Cancer Centers, and Academic laboratories. Strategic collaborations have covered all aspects of the IVD process –development, quality control, regulatory compliance, manufacturing (We are ISO-13485:2016, an FDA registered facility and GMP compliant), warehousing, distribution, product support, and commercialization. . Whether you need support for research, clinical trial testing or contract clinical testing services, we are here to serve. Above all, we believe in clear communication and transparency. We take a cross-functional team approach to our projects, fully engaging with our clients throughout the project. What do you need? Please contact us to see how we can support your business strategy!

Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world's largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize On 8/6/24 Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

Cosmos Health Inc. is a global healthcare group that was incorporated in 2009 in Chicago, Illinois. Cosmos Health Inc. is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia, and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmoshealthinc.com and www.skypremiumlife.com.

Couragene believes that delivery of gene and biologic therapies should be safer and more efficient. Delivery of genome modification therapies to brain is further complicated by the physiological barriers. Couragene's STEP (Stimuli-responsive Traceless Engineering Platform) technology has demonstrated great potential to overcome the delivery hurdles for treatment of various diseases, including neurogenetic disorders.

Courage Therapeutics is a pre-clinical biotech company focused on feeding behavior. The company has established a platform for creating receptor subtype

Courante Oncology is a full-service clinical research provider specializing in oncology product development. We offer a wide range of clinical trial management and support services to the pharmaceutical and medical device industries, including project management, clinical site monitoring, quality assurance, and medical writing servies. We believe the challenges of oncology clinical trials require a research team that is uniquely experienced and trained. Our strength lies in our collective experience and our ability to adapt to and meet our clients' specific research needs.

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

Our Mission is to treat diseases with first-and best-in-class covalent therapeutics for the most significant drug targets by leveraging our cutting-edge capabilities and expertise in chemistry, quantitative proteomics, translational sciences, and deep learning.

Founded in 2001, we are the third largest peptide-focused contract research, development, and manufacturing organization (“CRDMO”) worldwide in terms of sales revenue in 2023, according to Frost & Sullivan. We are also considered one of the most comprehensive peptide-focused CRDMO globally (Frost & Sullivan), offering complete life-cycle support from early-discovery, pre-clinical research and clinical development to commercial production. We mainly provide (i) contract research organization (“CRO”) services, including peptide new chemical entity (“NCE”) discovery synthesis; (ii) contract development and manufacturing organization (“CDMO”) services, including peptide chemistry, manufacturing, and controls (“CMC”) development; and (iii) contract manufacturing organization (“CMO”) services, including peptide NCE and generic drug commercial manufacturing. We have established global operations, with projects covering over 50 countries, including major markets in the United States, China, Japan, Europe, South Korea, and Australia. We also provide customers wit peptide drug development, production, and CMC filing support services that meet regulatory requirements in major markets worldwide. In addition to peptides, we have developed a diverse project pipeline focusing on various types of complex peptide- and oligonucleotide-based new chemical entities (“NCEs”). Our peptide conjugation services seamlessly integrate our peptide and oligonucleotide platforms to produce a wide range peptide conjugates products. The introduction of our PeptiConjuXTM and PeptiNuclide LinkTechTM are dedicated to the development and large-scale manufacturing (i.e., kilogram-scale) of peptide-oligonucleotide conjugates (“POC”), peptide drug conjugates (“PDC”), and radionuclide drug conjugates (“RDC”). As of December 31, 2023, we had successfully synthesized approximately 1,800 molecules through these two platforms.

A vision of developing an interdisciplinary program utilizing public and private partnerships to engage in research to foster development of a regional biofuels industry. In addition to the research and development of alternative fuels, EKU CRAFT researches the applications of alternative energy sources for the production of plastics, pharmaceuticals, and other petroleum-based products.

Creative Bioarray uniquely pioneers the development of high quality tissue, antibody, protein and cell array technology to efficiently analyze the concurrent expression and function of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction from a single biological sample. Creative Bioarray is a well-recognized service provider propelled by integrity, expertise and the desire to contribute to simplify, improve, and accelerate research speed of the scientists by providing the highest standard quality research products and services. Since it founded, Creative Bioarray had recognized that an important obstacle to make development of basic bioscience and preclinical researches using human specimens is the lack of access to reference materials. Consequently, Creative Bioarray was determined to be the first commercial entity specialized in building up the largest tissue-sharing platform by integrating the detailed clinical information of all the tissue samples.

Creative Biostructure is specialized in providing cost-effective contract services to both academia and biotech/pharmaceutical industries in the field of structural biology and membrane protein technologies. We have developed all-in-one, gene-to-structure pipelines for the structure determination of macromolecules of your interest. With a team of experienced professionals, Creative Biostructure is able to solve the structure of many challenging proteins including GPCRs, ion channels, transporters, enzymes and viral targets. We also provide a comprehensive list of products and other related services to facilitate your research in structural biology. Creative Biostructure has also built up a unique and comprehensive Membrane Protein Screening Platform. Aiming at elucidating the fundamentals of membrane protein systems, we provide gene-to-structure services on the purification, crystallization, structure determination and analysis of various membrane proteins. With our state-of-the-art platforms, we are offering our customers access to the latest tools, techniques and expertise for their structural biology projects with competitive pricing and short turnaround time. Our staff will be very glad to discuss the details of your project and develop experimental strategies tailored to your requirements.

Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. They offer custom peptide synthesis, process development, manufacturing as well as catalog products for customers in industry and research area.

Credence MedSystems is setting a new standard in drug delivery, helping drug manufacturers differentiate their products through innovative delivery systems while preserving trusted processes. Credence is an innovator in injectable drug delivery devices, offering our pharma partners a simplified path to commercialization of a best-in-class delivery system. The Companion Safety Syringe System was born from Credence's philosophy of Innovation Without Change, allowing our customers to impress and protect their end users while preserving their existing processes, sourcing strategies and preferred primary package components. The Companion is available in luer needle, staked needle and dual chamber reconstitution configurations. Across the platform, the user performs the injection, receives end-of-dose cues and then the needle automatically retracts into the syringe, preventing reuse.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Crown Aesthetics, the premier medical aesthetics company, is dedicated to helping leading plastic surgeons, dermatologists, and aesthetic physicians around the world grow their businesses. We do that by delivering dramatic results in rejuvenation and restoration. Our non-invasive innovations – SkinPen®, the first FDA-cleared microneedling device; the post-microneedling protocol Skinfuse® and the platelet-rich plasma system ProGen™ – act as "gateway" products that draw new consumers to practices. Based in Dallas, Texas, Crown Aesthetics sets industry standards for efficacy, safety, and innovation. As a result, our customers consistently deliver the best aesthetic care in the business. Learn more at CrownAesthetics.com.

Cullinan Therapeutics is a biopharmaceutical company dedicated to creating new standards of care for patients. They have strategically built a diversified portfolio of clinical-stage assets across oncology and immuno-oncology, as well as autoimmune diseases. The company is focused on developing innovative therapies to address unmet medical needs and improve patient outcomes.

Culture Systemsdevelops and deliver high quality natural ingredients for the dairy, nutritional, and food industries. Their product line includes cultures, dairy ingredients, enzymes, functional proteins, as well as contract-based research and production. Their ingredients are used in the food, pharmaceutical, nutritional and agricultural industries.

Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes FDA-approved branded prescription products. We are the largest publicly listed biopharmaceutical company founded and headquartered in Nashville, Tennessee. Nashville has become a leading center for health care in the United States, with over 300 companies headquartered here, and working in that industry. Cumberland is collaborating with Vanderbilt University and the Vanderbilt University Medical Center through a growing number of research and development programs. We are devoted to improving the quality of patient care and addressing poorly met medical needs. With a focus on underserved niche markets, we deliver products that serve patients in the U.S. market as well as internationally through select partnerships. Our commercial organization supports our branded products in the U.S., while our development team is working on new medicines for the future. Our primary focus is to improve patient care by providing differentiated products that offer clear advantages over other treatments. We also strive to deliver solutions that may help reduce costs for healthcare providers and, ultimately, patients.

We Focus on Identifying, Acquiring and Developing Disease-Modifying Therapeutic Drug Candidates with Rare Disease Indications

Curemark is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for neurological and developmental disorders. Our diverse pipeline spans multiple critical areas of unmet need, including Autism Spectrum Disorder (ASD), Amyotrophic Lateral Sclerosis (ALS), Addiction, Attention-Deficit/Hyperactivity Disorder (ADHD), Schizophrenia, and Parkinson’s Disease. At the heart of our mission is a commitment to addressing the root causes of these conditions, not just managing symptoms. Our lead investigational therapy targets key enzyme deficiencies associated with autism, offering a novel approach to treatment for a condition that affects millions worldwide. Our pipeline reflects a science-driven, patient-first approach with a focus on discovering and developing transformative therapies for complex neurological conditions. By exploring the role of enzymes and their impact on brain function, Curemark aims to deliver targeted, effective treatments that improve patient outcomes. With a commitment to scientific excellence, strategic collaboration, and a deep focus on patient well-being, Curemark is reshaping the future of neurological care. Our goal is to offer life-changing solutions for individuals living with autism, ALS, addiction, ADHD, schizophrenia, Parkinson’s disease, and other challenging conditions. Stay connected with us as we continue to push the boundaries of discovery and bring new hope to patients, families, and caregivers. For more information, visit Curemark.com.

CURE Pharmaceutical is an innovative drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. Our mission is to improve people's lives by redefining how medicines are delivered and experienced.

Cure Rare Disease™ is developing advanced therapeutics for those who have been diagnosed with rare, genetic diseases that have no treatment or cures. Through partnerships and collaboration, our world-renowned researchers build life-saving therapeutics that are intended to stop or reverse the progression of disease.

Our brand name and formulations amalgamate the knowledge of modern research in dietary supplements and the traditional wisdom of Indian system of medicine- Ayurveda. Cureveda’s innovative formulations are supported by knowledge and established trust which Baidyanath - pioneers in herbal formulations, has accumulated since 1917. Cureveda will provide you solutions for digestive issues, bone and joint care, arthritis, hair & skin health, sexual wellness, immunity, urinary & kidney healthy, liver health etc. and address ways for you to be fit body, mind and soul.

Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 25 global sites and 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecule offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com ************************************************** ⚠️NOTICE: Please Be Aware of False Employment Opportunities ************************************************** Please be aware there has been reported fraudulent activity within our industry regarding false offers being made to applicants and requests for personal information from individuals or organizations posing as company representatives. Any applicant who applies to Curia must submit their application through Curia’s career page at https://careers.curiaglobal.com. Applicants will only receive communication, including offer letters, from a curiaglobal.com email address. Please be aware that recent scams used email addresses that are similar to Curia addresses or use other public domain addresses such as gmail.com, yahoo.com and aol.com. Please confirm the sender’s email address prior to sharing your information.

Curie Co fashions biological solutions from the basic building blocks of life. Curie Co’s enzyme optimization platform teaches abundant, naturally-occurring enzymes to perform the same function as legacy preservatives and with efficiency that is orders of magnitude better. Our enzymes are gentle for people and the planet–they are fully biodegradable and sustainably derived. From hand soap, body wash, hair care products, skincare, and beyond, we give product formulators the freedom to build a powerful, long-lasting product that is nature-based from the bottom up. Founded in 2017, Curie Co is a collection of top scientists from Fortune 500 companies around the globe. Our interdisciplinary team unites under the belief that sustainability is not a luxury, it’s our obligation. Curie Co is proudly based in Research Triangle Park. To learn more, please visit: https://www.curieco.com/.

Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics or the treatment of cancer. The Company currently has three drug candidates in development: - Emavusertib (CA-4948), an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma and in a separate Phase 1 trial for acute myeloid leukemia and myelodysplastic syndromes. - CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation, or VISTA signaling pathway, being investigated in a Phase 1a/1b trial in patients with solid tumors. - Fimepinostat, an orally available, small molecule inhibitor of HDAC and PI3K enzymes, which is currently being evaluated for future studies. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. We are seeking dedicated, driven, humble, hands-on professionals, from diverse backgrounds, who are passionate about making a difference in the lives of patients and families touched by cancer, and who want to have some fun while doing it. For more information, visit Curis's website at www.curis.com.

Curtana Pharmaceuticals is a privately-held, preclinical-stage biopharmaceutical company developing first-in-class, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system (CNS) for the treatment of glioblastoma (GBM) and other brain cancers.

Curza is a small molecule therapeutics development company. Curza has developed a new class of antibiotics that are active and selective against Gram-negative pathogens.

Validation Consulting

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Cyclarity Therapeutics, Inc. is pursuing a mission to treat, cure, and reverse atherosclerosis. The company aims to deliver simple and affordable therapies for cardiovascular disease and other chronic diseases of aging. Cyclarity is continuing to develop technology to treat the underlying causes of age-related diseases.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company applying neurological insights to discovery, develop, and commercialize innovative medicines for people with serious diseases of the central nervous system (CNS). Lead programs include IW-6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv).

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is conducting a Phase 2b clinical trial using Trappsol® Cyclo™ intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

Cypris Therapeutics is a chemistry-focused pharmaceutical start-up that uses proprietary synthetic chemistry and drug development skills to produce effective therapeutics. The company has launched as the newest Ichor Life Sciences portfolio company and has secured over $500k in pre-seed funding. As the company moves forward, it continues to seek additional funding and partnerships to support its ambitious goals.

CytoAgents is developing innovative pharmaceutical products to treat life-threatening conditions, diseases, and disorders associated with Cytokine Release Syndrome (CRS). Led by CEO Teresa Whalen, CytoAgents is comprised of seasoned business leaders and medical professionals focused on developing innovative treatments. The company is a clinical-stage biotechnology company with a therapeutic focus on oncology.

Cytogel is a clinical stage bio-pharmaceutical company developing first in class drug candidates from the novel endomorphin family of molecules, that target key pain pathways and alleviate pain. This groundbreaking approach is backed by new technology to deliver treatment to people in pain. Learn how we’re reinventing pain management.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.

At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.us. See our community guidelines here: https://bit.ly/4fLkZS8

Dandelion Science is a US-Swiss Generative Neuromodulation™ company, committed to advancing precision therapies for vision and brain disorders. Led by a world-class team, Dandelion's mission is to enhance the lives of people affected by these conditions through the integration of advanced generative technologies and deep scientific expertise. The company boasts extensive intellectual property and has received prestigious funding from the US National Institutes of Health and the Swiss Innovation Agency.

Daré Bioscience® (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate a better quality of life for women. Vaginal drug delivery is often the optimum delivery approach to achieve these objectives, and IVR technology has become one of our preferred investigational platforms. Our portfolio features innovative IVR technologies including our non-hormonal contraceptive Ovaprene®, which we believe has the potential to disrupt the contraceptive landscape by providing protection for one month, without the use hormones, and our suite of ethylene-vinyl acetate (EVA) matrixed IVRs that can provide flexibility in terms of drug loading, drug delivery, and modulation of release rates across a wide array of molecules, hormones, peptides and proteins, facilitating new indications and applications of the technology. Daré’s EVA IVR technology includes DARE-HRT1 for dual hormone replacement as a potential treatment for the vasomotor symptoms of menopause and DARE-FRT1 for vaginal progesterone delivery in support of fertility and the prevention of pre-term birth. In addition to its novel IVR technologies, Daré is developing a topical formulation of sildenafil, the active ingredient in the blockbuster product Viagra®, for the treatment of female sexual arousal disorder (FSAD) as well as a novel vaginal formulation of the selective estrogen receptor modulator (SERM) tamoxifen to address and alleviate the symptoms of vulvar vaginal atrophy (VVA) for women diagnosed with and treated for hormone-receptor-positive (HR+) breast cancer.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Deaton Engineering, Inc. (DEI) is a nationally established, full-service mechanical, electrical, software control engineering and integration company located in Georgetown, Texas. Established in 1991, DEI offers a wide variety of solutions and services to a broad range of industries with a focus on turnkey engineering and product development services for the life-sciences industries. Composed of a diverse group of Texas licensed Professional Engineers, engineers, designers, and technical staff, Deaton Engineering develops ideas or products from concept through implementation.

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Engineering broad acting antivirals that target the viruses of today and pre-emptively protect against the viruses of tomorrow.

Deep Apple Therapeutics is writing a new playbook for drug discovery, leveraging a powerful combination of cryo-EM enabled structural biology, AI-powered pocket extraction, and more. The company is advancing multiple programs focused on GPCR modulators, a proven target class with applications in metabolic disorders.

DeepCure is transforming the field of small-molecule drug discovery, by delivering better drugs in a faster and cheaper way. The company was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. DeepCure does not use AI to simply generate a profile of the target candidate profile (TCP), but instead re-engineers drug discovery to deliver transformative results.

Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.

Applying novel, high throughput screening technologies to deliver therapeutics that address the most difficult problems in clinical medicine

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

DelNova, Inc. is an innovative drug development company targeting unmet medical needs, including complications arising from the use of botulinum toxin (e.g., Botox®, Dysport®, Xeomin®, Jeuveau®). Our first product under development, ReViVox™ (U.S. patent allowed), is based on a clinically validated drug and will address the impacts of unintended localized paralysis from therapeutic and aesthetic botulinum toxin [BoNT] injections. There is currently no reversal agent to safely resolve these side effects; patients can wait weeks or months for drug-induced paralysis to subside. Business Summary: DelNova is developing innovative therapeutics based on an in-depth knowledge of drug delivery. Many unmet patient needs are addressable by modifying the use of known drugs to target delivery for a more efficacious, yet safer outcome. The first product under development is based on a known drug, currently approved for use in other medical conditions and with a different route of administration. The novel formulation will be used for the reversal of undesirable side effects resulting from neurotoxin injections [eg. BOTOX (TM] in both medical and cosmetic uses. Problem: Botox™ (or other BoNT) injections may result in temporary, but undesirable side effects. Transient adverse effects are due to neurotoxin infiltrating into nearby tissue, causing unintended localized paralysis. This could be attributed to either poor injection technique and/or toxin spread. There is no reversal agent to safely mitigate unintended adverse effects; the only option is to wait until the effect of the drug paralysis subsides (weeks to months). For cosmetic procedures, side effects may include droopy eyes or brows, arched eyebrows, or misalignment . In some medical procedures adverse effects may include weakened neck muscles (for migraine ) or difficulty urinating ( for overactive bladder) . Solution: ReViVox(TM); a reversal / rescue product for muscle recovery post BoNT treatment.

Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.

Delpor is a clinical stage life sciences company that utilizes innovative drug-delivery technologies in order to develop once-yearly therapies for chronic conditions. The Company’s lead product is a 6-12-month formulation of Risperidone (drug/device combination product) for the treatment of schizophrenia. Delpor is also pursuing 6-12 month formulations of other drugs targeting CNS conditions including Neuromuscular Diseases, Neurodegenerative Diseases, Addiction, and other disorders.

DemeRx is a clinical stage pharmaceutical development company advancing drug candidates as therapies for addiction.

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.

Denison is a leading provider of turnkey formulation, manufacturing and packaging solutions for the branded OTC, Rx, and Cosmetic markets. Our product dosage forms include liquids, suspensions, creams, lotions, gels, and ointments. Located in Lincoln, Rhode Island, our state-of-the-art manufacturing site offers manufacturing and packaging of short, medium, and large production runs. In addition, our company maintains two sophisticated laboratories capable of providing a full suite of formulation development and analytical services.

Denovo Biopharma is a private San Diego based biotech company, also operating in China, providing a novel biomarker solution to personalize drug development. The core technology of the company is its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy or side effects. By identifying biomarkers correlated to patients'​ responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in targeted patient population to achieve higher efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in most therapeutic areas, such as oncology and neurological diseases.

DepYmed is currently developing potent inhibitors of the enzyme PTP1B as therapeutics for cancer and rare diseases. In addition, DepYmed has developed a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer. ​

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company’s lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.

Dermata Therapeutics, Inc. (Nasdaq: DRMA) is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is currently under clinical development for the treatment of acne, psoriasis, and rosacea. Our second product candidate, DMT410, uses our Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic skin conditions.

DermaXon targets the brain-skin connection to discover and develop novel therapeutic strategies to treat life-threatening diseases and disorders such as pain, pruritus and genetic disorders of skin keratinization. The company core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology. This polypharmacological approaches aim to understand and optimize the unknown off-targets activities for existing small molecules such as cannabinoids or retinoic acid. DermaXon uses medicinal chemistry, molecular biology and RNA sequencing to characterize and identify synergies and overlaps between biological signaling pathways modulated by small molecules.

It all started 40 years ago, when we dedicated ourselves to finding scientific solutions using components from natural sources such as Quillaja and Yucca. Since then, Desert King has been leading the way in responsibly sourcing and reliably delivering saponin based products to the world. We are a company based in the United States, Chile, and Mexico. From these locations, we supply products to more than 1,000 customers worldwide, all of whom endorse the quality of our products. We maintain long-term relationships of trust with our customers, reaching more than 60 countries. Our high value-added products provide solutions to global needs in a variety of industries, such as health, human and animal nutrition, cosmetics, mining and agriculture. This includes our QS-21, which is globally accepted as the human vaccine adjuvant quality benchmark. As pioneers in Quillaja domestication with more than 15 years of experience, we have established plantations to meet the growing worldwide demand while safeguarding the integrity of the native forest. Additionally, Desert King actively contributes to the protection and recovery of Quillaja Saponaria forests through sustainable development and harvesting techniques.

Polaris Pharmaceuticals, is a biopharmaceutical development and manufacturing organization (CDMO) specializing in biologics derived from microbial systems. We have manufactured clinical material for trials in the United States, Europe, China, Taiwan, Australia, and Korea. Polaris Pharma offers a comprehensive range of process and analytical development and high-quality cGMP pre-clinical and clinical manufacturing services. We offer services for the following: • Process Development • Master and Working Cell Bank Propagation • Pre-Clinical/Clinical Manufacturing • QC Method Development • In Process Testing • Release Testing • Stability Storage and Testing • Availability to provide high purity WFI and PW • Custom Buffer and Media Manufacturing • Contract Filling, Labeling, Inspection • Microbial Based Fermentation Products

We are a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design’s lead program is focused on the treatment of Friedreich ataxia, followed by programs in Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.

Detekt is a life sciences product design and engineering firm. Over the last 15 years, the team has worked alongside both private and public companies to launch products that fulfill each client’s vision and successfully go to market.

Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. 

Diasome Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering hepatocyte cell targeting to restore hepatocyte metabolism and treat metabolic diseases. Restoring hepatocyte function addresses the root dysregulations in common metabolic diseases like diabetes, obesity, and dyslipidemia. Our therapies leverage the Hepatocyte's natural regulatory functions, aiming to deliver superior patient outcomes and improved disease management.

At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with chronic diseases. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is entering a Phase 1 clinical study soon. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline. Located in South San Francisco, we've built a team of experienced industry professionals dedicated to innovation in immunology drug development.

Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal cord injured individuals.

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.

Peptides

Diverse Biotech is an innovative, clinical-stage biopharmaceutical research company that is committed to discovering and developing novel therapeutics from its proprietary drug platform.

DKP Genomics is a bioinformatics CRO. We provide top-quality computational biology analysis and bioinformatics infrastructure support to biotechnology, pharma, and agricultural companies and to research foundations. With nearly 15 years of experience in both biotech and major pharma, we're well versed in the standard analyses as well as advanced analyses to help identify targets, biomarkers, compound mechanisms, and advance the understanding of biological pathways and systems in multiple areas: microbial systems, diabetes / obesity, frailty, cancer, and neuroscience. More information can be found at http://www.dkpgenomics.com

DMXi makes oral care products based on peptides derived from the Amelogenin protein. Their products are designed to strenghen, desensitize, and brighten teeth.

DNA Technologies presents a unique anti-counterfeiting and brand protection solution to the marketplace through its combination of synthetic, DNA-laced security markers. We are dedicated to helping manufacturers, authenticators, license & trademark holders, governments and publishers worldwide eliminate the production and distribution of counterfeit goods. DNA Technologies uses expert knowledge to construct unique, synthetic DNA sequences that can encode company and product-specific information into inks, dyes and resins, to provide the ultimate security marker – the DNA MatrixTM. DNA Technologies has become the recognized leader in providing security marking and unequalled protection for valuable products, brands and intellectual property. This patented and proprietary technology has been used to protect the products and brands of Thomas Kinkade, Major League Baseball, the National Hockey League, the Super Bowl, Hanna-Barbera, BRL Hardy's Wines and the 2000 Sydney Olympics.

Dogwood is pioneering Halneuron®, a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer pain, and other pain indications. It is also developing the antiviral combination therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”)

Double Rainbow is leveraging the critical role of glycans in human biology to bioengineer anew class of glyco-drug conjugates (GDC) and deliver the next generation of precision medicines.

DP Clinical, Inc. is a privately held Contract Research Organization (CRO) specializing in neurology/CNS (including spinal cord injury), oncology, ophthalmology, infectious disease/vaccines, and rare disease Phase I-IV clinical programs. DP Clinical provides a full complement of clinical trial services to pharmaceutical, biotech, and medical device companies including trial management, monitoring, data management, biostatistics, regulatory, safety monitoring and reporting, and medical writing. Since 1994, we have worked for clients of all sizes — small to large pharmaceutical and biotech companies, academic research institutions, and government sponsors. DP Clinical provides integrated trial solutions as well as specific service components based on sponsor need. Our comprehensive services include: • Project management • Clinical trial monitoring • Data management • Biostatistics • Pharmacovigilance and safety • Regulatory affairs • Quality assurance • Medical writing

DPT Laboratories CDMO Services is a pharmaceutical contract development and manufacturing organization specializing in semi-solid and liquid dosage forms, with a legacy of excellence dating back 80 years.

Private biotech company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types.

Dr. Reddy's Laboratories is a pharmaceutical company that specializes in pharmaceutical manufacturing and healthcare products.

Pain controlling device

DSG, Inc. is a leading global eClinical provider with a fully unified suite of innovative technology solutions and data management services for the global clinical research community. DSG's eClinical software platform provides competitive advantage that is cost-effective with on-time project delivery. DSG solutions have been used in thousands of clinical trials around the globe with our award-winning eCaseLink™ platform and eCaseLink Designer for enterprise licensing. Founded in 1992, the company is proud to be recognized as the first provider of a fully integrated EDC and IRT Randomization and Trial Supply Management system with the SCDM Data Driven Innovation Award. For more information, please visit www.dsg-us.com

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcoholic hepatitis (AH), COVID-19 patients with acute liver or kidney injury, and nonalcoholic steatohepatitis (NASH).

DxTerity is bringing the power of precision medicine to autoimmune disease. We are pioneering the use of RNA-based immune system profiling to better understand the root causes of immune mediated conditions. Our goal is to provide more personalized care for autoimmune sufferers and empower patients with more detailed information about their condition so they can better navigate their complex health journey.

Dyad Labs (A Mérieux NutriSciences Company) is an ISO/IEC 17025:2017 accredited contract laboratory providing specialized chemistry and microbiology testing services to the Nutraceutical and Food & Beverage industries since 2008. Dyad Labs’ mission is to professionally, effectively, and ethically perform testing for our customers to produce accurate and precise results while offering exceptional customer service and support by meeting and exceeding customer expectations. Led by a management team of experts that have diverse backgrounds in pharmaceutical, nutraceutical, and bioanalytical research fields, Dyad Labs is constantly working on new technologies that offer cutting edge solutions to increasing regulatory requirements and calls for full transparency of the supply chain.

GDIT is a global technology and professional services company that delivers consulting, technology and mission services to every major agency across the U.S. government, defense and intelligence community. Our 30,000 experts extract the power of technology to create immediate value and deliver solutions at the edge of innovation. We operate across 30 countries worldwide, offering leading capabilities in digital modernization, AI/ML, Cloud, Cyber and application development. GDIT is part of General Dynamics, a global aerospace and defense company. We have shared our clients’ sense of purpose for over half a century and have a have a unique understanding of their missions, complex environments, and a rapidly changing world. Together with our clients, we strive to create a safer, smarter world by harnessing the power of deep expertise and advanced technology.

At Dyve Biosciences, we leverage our proprietary transdermal platform to deliver intuitive, targeted pH modulation to treat a range of immunologic and oncologic diseases. By directly targeting the acidic microenvironments that drive cancer cell growth and inflammation, we are taking decades of proven science from the petri dish to the patient.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and Byfavo® and Barhemsys® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

EIG's mission is to develop highly accurate and non-invasive multi-omic molecular testing solutions for complex diseases like cancer. The company has developed a Multi-omic Integration Platform that combines detection of DNA, RNA, protein and metabolite targets into a single assay. This breakthrough approach transforms the field of molecular diagnostics by offering unparalleled accuracy with comprehensive insights for early disease detection. www.earlyisgood.com.

亿腾医药从2001年成立以来，始终以链接全球优质药品与病患，成为中国领先的专利及品牌药物供应商为愿景与使命。一方面我们“传承经典”，持续收购全球跨国药厂著名的经典品牌产品，通过与有效的运营成本管控和中低端医疗机构拓展，使更多中国病患从品牌及专利药物中受益。另一方面我们不断“开拓创新”，持续引进海外研发机构的专利药物，参与国际多中心临床试验，力争在中国与国际同步上市新药，为临床医生提供更多对疾病的治疗手段。多年来我们快速拓展业务，在多领域进行战略部署，目前正在逐步从引进研发营销型组织升级成为全产业链组织。 我们已在全国30个省拥有近1,000名专业学术推广人员，覆盖了19,000多家医院和超过20,000家药房。多年来，我们和跨国医药企业、专业医药公司、领先研发机构合作，通过授权引进专利药物、成立合资公司、资产并购、建立战略联盟、独家经销等形式，不断丰富包括抗感染治疗、抗肿瘤治疗、呼吸系统疾病治疗、心血管疾病治疗、肾科疾病治疗在内的多领域药物产品组合。 此外，我们在研的几款新药也可望于近期上市。其中具有变革意义的VASCEPA®（二十碳五烯酸乙酯，原名AMR101）胶囊，已被证明可明显降低相关患者群体的甘油三酯水平而不升高LDL-C水平，其降低多种心血管疾病风险的试验结果也先后发表于2018年11月的《新英格兰医学杂志》和2019年3月的《美国心脏病学院杂志》。近期， 美国FDA又正式接受了VASCEPA®胶囊用于降低心血管风险补充新药申请（sNDA），并同时授予了优先审评资格。亿腾自2015年获得VASCEPA®中国大陆以及港澳台地区的开发、商业化及供应等活动，包括这项关键性注册临床研究的管理和资助。我们已经在中国完成了一项药代动力学（PK）研究以及一项中美健康受试者PK特征的种族差异比较研究；目前正在开展一项III期临床试验。 “专业、卓越、责任、执着”是亿腾的价值观。我们的职业和生命与健康相关，专业是最基本准则，精益求精的原则贯穿于我们工作的每一个细节，尽忠职守是我们对于每一项任务的基本态度，面对信念和使命，我们百折不挠永不放弃。为了让中国患者使用到全球最优质的药品和领先的医疗技术，我们砥砺前行。

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

We formed Edgewood Oncology because of the synergistic mechanism of action and promising safety and anti-tumor data that was observed with BTX-A51 in Phase 1 in AML and solid tumor patients. We look forward to further developing this compound using a precision medicine approach in patient populations who lack effective treatment options. — David N. Cook, Ph.D., Chief Executive Officer

EicOsis is a small start-up company located in Davis, CA focused on developing non-opioid treatments for pain in humans and animals.

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. They are pioneering a new method of drug discovery based on tracking and measuring movement of molecules within living cells. The company leverages superior engineering and high-performance computing to analyze single molecules and discover innovative medicines.

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.

Eldec Pharmaceuticals Inc. is a preclinical biotech company focused on developing novel peptide therapeutics to treat inflammatory and autoimmune diseases. The company was spun out of the University of North Carolina at Chapel Hill (UNC-CH) in 2017 and is currently developing peptide-based therapies to treat lung infections and lung inflammation.

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, Hypercon™, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are headquartered in Boston and innovate globally. Formulating the Future of Biologics™. www.Elektrofi.com

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas. We develop and assess therapeutics based upon their ability to make a meaningful impact for patients and their treatment experiences. We invest in proven and promising therapeutics at various stages of development and advance them through clinical and regulatory processes with the goal of commercializing improved treatment options for patients and the healthcare providers who treat them.

Eliem Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapies for neuronal excitability disorders with the goal of restoring balance in both the peripheral and central nervous systems to help patients live on their own terms. Eliem channels its experience, energy, and passion for improving patients’ quality of life by developing life-changing novel therapies for disorders such as chronic pain, depression, epilepsy, focal onset seizures, and anxiety – conditions that make simple daily activities challenging for impacted patients.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Elim Biopharmaceuticals, Inc. is a leading life science service company for the biotech, pharmaceutical, and medical communities, offering a range of services from sequencing to synthesis, including drug quantification.

Elion Therapeutics is a cutting-edge biotechnology company dedicated to transforming the treatment of life-threatening fungal infections using a novel approach that’s rooted in structural chemistry. Elion was founded with the belief that mechanistic insights enable targeted optimizations of natural products. Today, Elion is advancing the first polyene antifungal rationally designed to mitigate toxicities and increase safety.

Elite Pharmaceuticals is a pharmaceutical company that specializes in drug manufacturing and healthcare solutions.

Elorac, Inc. is a specialty pharmaceutical company devoted to developing, commercializing, and marketing dermatology products. Elorac has over 20 novel prescription products in development. Our products embody proprietary technologies or compounds, all protected by patents or covered by proprietary technology.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.

Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 11th largest company in Indian Pharmaceutical Market as per AWACS MAT Feb'24 data.

Emerald Cloud Lab® (ECL®) provides researchers from various disciplines with access to state-of-the-art scientific labs from anywhere on earth, 24 hours a day, 365 days per year. With ECL researchers utilize a single software interface to securely design, run, and analyze experiments, allowing researchers to spend more time designing protocols and analyzing data, and less time on mundane time-intensive activities in the lab. With ECL every researcher utilizing the platform becomes more productive, and more efficient while reducing operational costs and the impact on the environment.

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Emergo Therapeutics: Bringing the Immune Response back into Balance

Emery Pharma (EP) (emerypharma.com) is a FDA registered/inspected, DEA licensed, and cGMP/GLP compliant full service contract research laboratory specializing in microbiology & cell-biology testing, medicinal chemistry, analytical chemistry, and bio-analytical services. EP is located in Alameda, CA, at the heart of San Francisco Bay area. We have been supporting clients both locally and globally. We have deep expertise in drug development and support clients from early preclinical all the way to Phase 3 clinical program. Our Bioanalytical Chemistry team utilizes the state of the art LCMS-MS instrument to unravel the targeted compounds in blood, plasma, skin, etc- We provide assistance with R&D method development, validation, method transfer and analytical services. Medicinal Chemistry: Our team has expertise in diverse therapeutic areas covers all aspects of medicinal chemistry, from strategic planning to hit evaluation and validation to lead optimization and pre-clinical development. Analytical Separation Chemistry: Utilizing NMR, LC-MS, HPLC, GC-MS. Microbiology: Spectrum of Antibacterial and Antifungal Activity, Biofilm Profiling, Resistance Profiling, Cytotoxicity Testing, Microscopy Services, Tissue Efficacy Modeling

With over 25 years of experience, EMINENT, headquartered in Maryland, is a specialist in offering comprehensive services for pharmaceutical drug development and clinical management. Our services extend across the full development spectrum, from the initial characterization of bulk drugs to the final product launch. We are adept at supporting pharmaceutical and biotechnology companies, as well as academic institutions and Contract Research Organizations (CROs), by providing customized solutions to meet a variety of needs. These needs include drug formulation, stability testing, clinical manufacturing, patient-specific packaging, randomization, distribution, monitoring of drug products at clinical sites, patient compliance tracking, return drug accountability, and the storage of biological specimens.

Emmyon - Discovery and development of small molecules that improve muscle mass, strength and metabolism Commercialization of small molecules through licensing agreements and partnerships with consumer-facing companies Funded by private investors and the National Institutes of Health

Empyrean is harnessing the power of genetic engineering to transform how we treat severe neuropsychiatric and neurologic diseases.

Emtora Biosciences is a life science company developing a novel formulation of rapamycin, eRapa™, for use in preventing the onset and recurrence of cancer. A Phase 1b safety and dosing clinical trial is underway in early stage prostate cancer patients. A pilot efficacy study in Familial Adenomatous Polyposis (FAP) is planned for late 2019.

Enalare Therapeutics Inc. is a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, including respiratory depression caused by drug overdose, post-surgery, and other conditions. The Company is planning to initiate pivotal studies for its lead compound ENA-001 in the near term.

Enanta Pharmaceuticals is using its robust chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and liver diseases. Enanta’s research and development efforts are focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), hepatitis B virus (HBV), human metapneumovirus (hMPV) and SARS-CoV-2.

ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.

Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company’s second investigational candidate, ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition resulting in a reduction of oxygen that reaches the blood stream and vital organs. Few effective therapeutic modalities exist to treat ARDS, leading to a high mortality rate. ENDECE designed NDC-1308 to reduce the ability of SARS-CoV-2 / COVID-19 to replicate within the pulmonary system, and reduce inflammation.

EndoCyclic Therapeutics is a biopharmaceutical company engaged in the development of the first non-hormone therapeutic for endometriosis.

Endolytix Technology, Inc is developing a new therapeutic approach that addresses antibiotic resistance in nontuberculous mycobacterial infections (NTMs)

At Endo, our far-reaching vision is simple: to help everyone we serve live their best life. As a specialty pharmaceutical company, we’re motivated by a strong sense of purpose to find better ways to meet unique medical needs. Our global team of passionate employees understands the importance of their work. We’re dedicated to supporting one another as we connect with communities and foster partnerships that elevate quality-of-life and bring the best treatments forward. Our uncompromising commitment results in the delivery of life-enhancing therapies. From intelligent product selection to commercialization, we strive to make a meaningful, tangible impact to help everyone live their best life. Endo has global headquarters in Malvern, Pennsylvania. Community Guidelines: 1. Be respectful. Everyone who visits our page should feel comfortable and respected. 2. If we see a comment that violates anything in the following list, it may be removed. • Comments that use profanity; personally attack or bully another individual; or are off-topic, misleading, factually inaccurate, political, spam, defamatory, discriminatory or promotional. • Comments that are excessively repetitive and/or disruptive to the community. • Comments that promote illegal activity, use copyrights or trademarks or are related to an ongoing legal matter. • Comments that appear to be medical advice. We reserve the right to remove a reply for any reason at any time. 3. Adverse Event Reporting: If we see a post about an adverse event, an Endo representative will need to contact you to find out more information to comply with regulatory guidelines. If you experience a side effect while using an Endo product, please consult your physician or pharmacist immediately. You may also report to the FDA at fda.gov/medwatch or 800-FDA-1088. Replies from other users do not necessarily reflect the views of Endo. We do not endorse content added by other users.

We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.

Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company's initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho's assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company's pipeline.

Ensigna Biosystems is a contract research organization that provides cutting-edge molecular pathology and genomic services to the biopharmaceutical industry. By combining traditional pathology services with genomics, Ensigna Biosystems is able to characterize biological samples based on protein expression, mRNA levels and mutational status, thus enabling the development of targeted therapies and the implementation of personalized medicine.

Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions.

Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. For more information visit www.enterothera.com.  Entero Therapeutics is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Entero’s niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients. Two additional formulations of niclosamide, FW-UC (ulcerative colitis) and FW-CD (Crohn’s disease) are expected to enter the clinic in 2022 and 2023, respectively. Entero is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. The Company is headquartered in Boca Raton, Florida with clinical operations in Hayward, California. For more information visit www.firstwavebio.com.

Entrinsic Bioscience is a biotechnology company that specializes in developing functional ingredients and Active Pharmaceutical Ingredients (APIs) through a proprietary platform centered on amino acid combinations. The company utilizes a biomapping and electrophysiology platform to identify and patent specific amino acid combinations that influence protein regulation and cell signaling. This technology has its origins in research conducted with NASA, aimed at addressing gastrointestinal damage from ionizing radiation during deep space missions. The company offers a range of applications, including products for pulmonary health, digestive health, immune regulation, metabolism, hydration, and skin health. One of its notable products is enterade IBS-D, a non-prescription medical food designed to manage symptoms of IBS-D. Entrinsic collaborates with healthcare providers, academic institutions, and global partners to commercialize its formulations, focusing on science-backed, plant-based solutions that enhance health outcomes.

The company is using computational metabolomics, and knowledge graphs, to discoverthe next generation of small molecule therapeutics.

Enzon is a New Jersey-based biopharmaceutical company that develops and commercializes medicines for the treatment of cancer.

For over 30 years Enzyme Research Laboratories has been manufacturing and distributing a variety of enzymes and cofactors used in basic coagulation research.By constantly striving for products of utmost quality, ERL has earned the trust of coagulation research communities worldwide. ERL is dedicated to serving the research and diagnostic communities by offering a complementary line of monoclonal and polyclonal antibodies.

EOLO PHARMA is a pharmaceutical company that focuses on drug discovery and developing novel molecules for the treatment of obesity.

Powering relentless science by developing and commercializing first-in-class treatments to address debilitating and potentially fatal diseases, including COVID-19 and other infectious diseases; autoimmune diseases including rheumatoid arthritis; cachexia associated with AIDS or cancer; and topical non-invasive treatments for sight-robbing retinal diseases.

EpaleX is developing a novel inhaled treatment for epilepsy and migraine. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. When a seizure warning sign (aura) occurs, the patient will be able to prevent the development of a full-blown seizure through the use of a pocket nebulizer to deliver a powerful antiseizure medication that rapidly enters the brain and stops the seizure. The effect of the drug dissipates within minutes, allowing the patient to resume normal daily activity. The inhaler is also used to stop migraine attacks that are refractory to currently available migraine treatments.

EpicentRx is an innovation-driven clinical-stage drug and device company that puts the emphasis on “ease” - ease of treatment, ease of side effects, and ease of symptoms during the treatment of a range of diseases including lung cancer, and head and neck cancer, and different inflammatory disorders for which the company has received several grants and orphan designations. The lead device is called the eLOOP and the lead therapies are the direct NLRP3 inhibitor, nibrozetone (RRx-001), and the TGF-β trap-enhanced oncolytic adenovirus, AdAPT-001, in Phase 3, and Phase 2 clinical trials, respectively.

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices. For more information please contact us at info@epicsciences.com

Epigen employs hit-to-lead and lead optimization techniques. These encompass computational design, scaffold-hopping, focused library synthesis, and screening. They use in silico drug discovery tools, coupled with property assessment for Absorption, Distribution, Metabolism, and Excretion (ADME). These methodologies and processes scrutinize parameters such as physicochemical attributes, solubility, metabolic stability, CYP450 inhibition, hERG liability, oral bioavailability, central nervous system (CNS) permeation, toxicology, and in vivo effectiveness.

Epirium is a clinical-stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue function, potentially resulting in novel therapeutic approaches to currently intractable neuromuscular diseases. The company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration. Epirium is currently planning clinical trials with its initial drug candidate in Becker muscular dystrophy

EpiVario is a preclinical stage biotechnology company focusing on neuropsychiatric disorders. Our co-founders, Dr. Shelley Berger and Dr. Philipp Mews, are leaders in the field of neuroepigenetics. They identified a key metabolic enzyme that functions within the nucleus of neurons to activate genes critical for long term memory. This epigenetic mechanism plays a critical role in consolidating trauma-induced fear and stress responses and drug craving associated with addiction. Thus, providing a new target for treating memory-related neuropsychiatric disorders, such as PTSD and drug and alcohol addiction, and starting with nicotine addiction. An Expert Team Founded by epigeneticists at the University of Pennsylvania, EpiVario’s team leverages deep expertise in epigenetics and neuroscience, along with the commercialization of novel drugs. EpiVario’s co-founders are known and respected leaders in their fields, with more than 30 years of combined experience. A Strong Intellectual Property Portfolio EpiVario currently has PCT and U.S. patents pending, both related to the Company’s novel approach to targeting the ACSS2 gene. About Addiction and PTSD PTSD is a psychiatric disorder that can develop as a response to experiencing or witnessing a traumatic event, such as interpersonal violence, combat, or a life-threatening accident or natural disaster. Core features of PTSD include re-experiencing symptoms (i.e., intrusive memories, flashbacks, and nightmares), avoidance of reminders of the trauma, negative thoughts and feelings (e.g., amnesia for aspects of the trauma, anhedonia, withdrawal, exaggerated self-blame), and increased arousal (i.e., insomnia, irritability, poor concentration, hypervigilance). The severity of PTSD symptoms can intensify through cycles of memory recall and reconsolidation.

EpiVax uses immune-engineering to develop new vaccines and to improve the immunogenicity profiles of new drugs. The company is well known for its independent thinking and interdisciplinary scientists. Thinking outside the box at EpiVax has often led to paradigm-shifting discoveries. Responsibility is another key attribute: EpiVax counts 6 of the eight largest Biotech companies in the world among its clients. EpiVax is also globally responsible: the company supports a number of not-for-profits that improve human health around the world. The company was founded in 1998 with support from the Slater Biotechnology Fund. In 2002, EpiVax was invited by the FDA to participate in one of the first ever "Immunogenicity"​ meetings. By 2006, EpiVax had developed a reputation as “thought leaders” in the field of therapeutic proteins and immunogenicity screening, providing fee-for-service solutions for first tier Pharma companies, mid to small biotech companies, and academics. The company has a solid reputation for publishing its work in academic journals (>170 publications, compared to <20 for its competitors). The EpiVax team also prides itself on delivering on promises. “We maintain a close relationship with our clients,” De Groot says. We aim to treat our clients with respect and provide capable, intelligent solutions for their needs.” The company's motto is "Fearless Science"​. For up to date news about the endeavors of our Fearless Scientists, read our blog: http://epivax.com/press/thinking-out-loud-blog

Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19. The company has discovered small bispecific drugs that engage both cytotoxic immune cells and the virus. Binding of the drug to the virus leads to the destruction of the virus by the immune system.

Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn’t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.

Erimos is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics to treat cancer and viral diseases. We are dedicated to harnessing our innovative technology to meaningfully improve the lives and health outcomes of patients.

Official LinkedIn page for Esperion. At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc. Community guidelines: https://bit.ly/3vLCGdO Certified Great Place To Work®

Estrigenix Therapeutics, Inc. is a privately held pharmaceutical company developing the next generation of innovative therapies for improving the mental health of menopausal women. Menopause is associated with cognitive dysfunction, increased mood and anxiety disorders, and an elevated risk of Alzheimer’s disease, yet standard estrogen therapies are associated with increased risks of cancer, heart disease, and stroke. Our mission is to develop novel drugs that mitigate the adverse effects of menopause on mental health and enable women to live healthier and happier lives. The drug development program at Estrigenix focuses on selectively activating specific estrogen receptor proteins that promote memory formation, improve mood, and reduce anxiety. We believe that targeting these receptors will provide the cognitive and mood-enhancing benefits of estrogens without the harmful side effects of standard estrogen therapies. Our lead compound, EGX-358, is a potent and selective agonist of the estrogen receptor beta protein, which enhances memory formation in a mouse model of menopause. Current work is expanding the use of this compound to other indications, including depression, anxiety, and hot flashes.

Eton Pharmaceuticals, Inc. is a Deer Park, Illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway. Our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.

Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat brain disorders. Serotonin synthesis amplification is distinct from targeting serotonin transporters (e.g., SSRIs) and receptors (e.g., psilocybin). Evecxia deploys 5-HTP, the natural serotonin precursor, delivered via proprietary drug delivery technologies to achieve sustained serotonin synthesis amplification. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression when first-line SSRI/SNRI antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy for patients in acute suicidal ideation crisis. Evecxia holds a comprehensive portfolio of issued and pending patents on the 5-HTP sustained-release/serotonin amplification method, doses, formulations, and related technologies.

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company’s first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only vaginal pH regulator approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women.

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Exavir Therapeutics is a biotechnology company dedicated to developing nanomedicines for chronic disorders in virology and CNS, beginning with ultra-long-acting integrase inhibitors for HIV Treatment and HIV PrEP.

Exela Pharma Sciences LLC is a specialty pharmaceutical company based in Lenoir, North Carolina, founded in 2005. The company develops, manufactures, and markets both generic and proprietary sterile injectable and ophthalmic products. Exela aims to improve patient outcomes and reduce healthcare costs through its innovative offerings. With a workforce of 501–1,000 employees, Exela specializes in products that face high barriers to market entry, utilizing regulatory pathways like Abbreviated New Drug Approvals (ANDA) and 505(b)(2) submissions. The company focuses on delivering high-quality, affordable products that enhance the experiences of healthcare providers and patients, emphasizing ease of use and clinical effectiveness. Exela's product range includes sterile injectables designed for improved safety and faster preparation, as well as sterile ophthalmic solutions that meet strict regulatory standards. The company operates a vertically integrated model, managing development, manufacturing, and commercialization in-house, which supports its commitment to quality control and innovation in the pharmaceutical industry.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. The company’s initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options. Expansion is based in Jupiter, Florida

Exxel Pharma is a pharmaceutical company focused on the development of innovative, small molecule based medicines for management of pain and treatment of neuronal hypersensitivity disorders.

Eyconis is a newly formed company that will develop, manufacture and commercialize TransCon ophthalmology assets.

EydisBio is a small biotech startup based out of Durham, NC focusing on the development of a platform of small molecule therapeutics targeting a variety of diseases driven by aberrant inflammatory/autoimmune processes.

Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

At Faraday Pharmaceuticals, Inc., our mission is to improve quality of life for patients after acute critical illness by minimizing damage to cardiac and skeletal muscle.

FAR Biotech is a preclinical, computational drug discovery company that focuses on hard-to-drug targets that have high scientific and commercial value. Founded by Dr Martin Martinov after 25 years in academia and industry -- and named after the Bulgarian word “far” that translates into “lighthouse” or “beacon” -- FAR seeks to shine a light on drug discovery in areas of high unmet clinical need. FAR's proprietary technology can more rapidly identify novel, structurally diverse, optimized, lead molecules that other approaches would not look for, let alone find. The key differentiator is FAR's complete and rigorous quantum mechanical representation of drug-target interactions -- which embeds the advantages of quantum similarity and multi-property optimization for hit and lead identification -- augmented by AI / machine learning & big data. FAR's quantum biomodelling platform has been validated preclinically across a number of therapeutic areas, including neurodegeneration, oncology and infectious diseases.

Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders.

Fauna Bio is inspired by the untapped potential of non-model organism biology. We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.

Fennec Pharmaceuticals is a biotechnology company focused on improving the lives of children with cancer by addressing chemotherapy-induced hearing loss.

Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity in many patients, leaving many survivors of childhood cancer with permanent and irreversible hearing loss. Permanent hearing loss, even minimal, acquired at a young age has a devastating impact on development, education, and socialization and a lifelong negative impact on Quality of Life. There are no currently approved treatments for the prevention of platinum-induced hearing loss. At Fennec Pharmaceuticals, we are dedicated to the development of our investigational agent, PEDMARK™, for the prevention of ototoxicity in children, and we hope that this will enable more children to retain their hearing. In honor of our namesake, the fennec fox, we strive to embody adaptability and resourcefulness in everything we do. Please see www.fennecpharma.com for more information.

FERMWORX is a biotechnology company that specializes in producing high-performance biopolymer-based and bio-based fermentation products, offering product development and toll manufacturing services with a focus on renewable and sustainable practices.

Small Molecules, Contract Manufacturing

FGH BioTech develops novel drugs for metabolic diseases and cancer.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company’s lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn’s disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.